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ABSTRACT

THE ASSOCIATION BETWEEN MEDICATION ADHERENCE IN MENTAL
ILLNESS AND SUBSTANCE USE DISORDER RELAPSE IN PATIENTS WITH
DUAL DIAGNOSIS

By
Tyler Dunn
May 2018

Thesis supervised by Dr. Jordan Covvey

Objectives: The aims of the study were to (1) identify personal, social, and clinical
history for patients with substance use disorder (SUD) and mental illness, (2) measure
agreeance between patient self-report versus facility record history for mental illness,
substance abuse, and psychotropic medication, (3) investigate the specific role of
medication adherence and barriers to use for psychotropic medications upon SUD
relapse, and (4) assess follow-up changes in mental illness severity and medication
adherence in dual diagnosis patients enrolled in a substance abuse rehabilitation program.
Methods: The pilot study utilized a mixed methodology. Inclusion criteria included male
patients at least 18 years of age who were newly admitted at a 90-day residential
rehabilitation program with a self-reported diagnosis of SUD, and either major depressive
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disorder (MDD), bipolar disorder, generalized anxiety disorder (GAD) or schizophrenia.
Patients were evaluated within their first week of treatment and follow-up interviews
were conducted at 1 and 2 months. Facility records were accessed to cross-reference
patient reported data, using Cohen’s kappa coefficient to determine agreement. Patient
demographic characteristics, substance abuse characteristics, health-related
characteristics, and attitude towards medications stratified by adherence rates and relapse
rates utilizing ANOVA and t-tests. Pearson’s correlation coefficient was utilized to
analyze the relationship between medication adherence and SUD relapse. A multivariable
logistic regression model was created to assess the impact of adherence on relapse
frequency. Patient and clinical characteristics were stratified according to follow-up
interviews completed utilizing ANOVA and t-tests. Lastly, changes in patients’ selfreported adherence from interview to interview were analyzed using mean difference.
SPSS Statistics (IBM Corp; Armonk, NY) was utilized for all analyses, with a two-tailed
level of significance at 0.05.
Results: The final sample consisted of 38 patients. The majority of patients were white
(n=27, 71.1%), unemployed (n=32, 84.2%), and homeless (n=30, 78.9%). Heroin was the
most common primary drug of use (n=19, 50%), followed by alcohol (n=12, 31.6%), and
crack cocaine (n=4, 10.5%). The average length of substance use was 20.3 years. Half of
the patients (n=19, 50%) had two or more mental illness diagnoses and the most common
was the combination of MDD and GAD (n=9, 23.7%), followed by MDD alone (n=7,
18.4%), and bipolar disorder (n=6, 15.8%). Significant agreeance was found between
patient self-reported data to facility records for primary substance of use (κ=0.753,
p<.001), mental illness diagnosis (κ=0.434, p<.001), number of mental illness
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comorbidities (κ=0.257, p=0.008), and number of psychotropic medications prescribed
(κ=0.094, p<.001). Patients self-reported less comorbid diagnoses and more previous
treatment stays compared to facility records. Patients receiving income prior to admission
had higher relapse rates (16.9 vs 8.1, p=0.02). Self-reported relapse rate was negatively
correlated with the Morisky Medication Adherence Scale (MMAS-8) intentional score
(r= -.360, p=.026), MMAS-8 total score was positively correlated with self-reported
adherence rates (r=.618, p<.001), the MMAS-8 intentional score (r=.869, p<.001), and
the MMAS-8 unintentional score (r=.863, p<.001). MMAS-8 intentional score was
positively correlated with MMAS-8 unintentional score (r=.552, p<.001) and selfreported adherence rate (r=.613, p<.001). Lastly, the MMAS-8 score was positively
correlated with self-reported adherence rate (r=.481, p<.001). For the regression model,
MMAS-8 total score was a significant predictor of relapse rate (stand. beta = -.443, CI= 6.37-0.23, p=.048) but the linear combination of the measures included was not
significantly related to self-reported relapse rate (F=2.25, adjusted R2 =.145, p=.073). A
total of 12 patients (31.6%) fully completed the study, 15 patients (39.5%) only
participated in the first follow-up, and 11 patients (28.9%) only participated in the
primary interview. DAI-10 total scores were lower in patients who only completed the
primary interview vs. patients who completed the entire study (4.0 vs 7.0, p=.044). There
was a significant increase in adherence at the first (mean difference=5.7, p<.001) and
second (mean difference=6.5, p<.001) follow-ups compared to the primary interview.
Conclusions: The study provided valuable insight into the relationship between
psychotropic medication adherence and SUD relapse in patients with dual diagnosis
which can be used by healthcare professionals and drug abuse rehabilitation programs.
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CHAPTER 1 – INTRODUCTION
I.

Mental Illness
a. Definition, burden, and impact

Mental illness refers to a wide range of mental health conditions characterized by abnormal
thoughts, perceptions, emotions, and behaviors that result in suffering or poor ability to function
in life.1 The Diagnostic and Statistical Manual, 5th Edition (DSM-5) defines mental illness as “a
syndrome characterized by clinically significant disturbance in an individual’s cognition,
emotion regulation, or behavior that reflects a dysfunction in the psychological, biological, or
developmental processes underlying mental functioning.”2 A serious mental illness (SMI) is
defined as any mental, behavioral, or emotional disorder that substantially interferes with one or
more major life activities.3

Mental illness has a substantial impact on the population at-large. The World Health
Organization (WHO) World Mental Health (WMH) Survey Initiative is a project that aims to
obtain and assess accurate data about the worldwide prevalence of mental, behavioral, and
substance disorders in 28 counties across 154,000 individuals. The WHM Survey Initiative’s
most recent data from 2009 found the inter-quartile range (25th–75th percentiles across countries)
of mental illness prevalence in the participating countries to be between 18.1% and 36.1%. The
worldwide prevalence of SMI was estimated between 4% and 6.8% in half of the countries
surveyed, between 2.3% and 3.6% in one-quarter of the countries, and between 0.8% and 1.9%
in rest of the countries. A significantly higher 12-month prevalence of mental illness was found
in the United States (US; 27.0%), Ukraine (21.4%), Colombia (21.0%), New Zealand (20.7%),
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and France (18.9%) while Japan (7.4%), China (7.1%), and Nigeria (6.0%) had a significantly
lower prevalence.4

The National Survey on Drug Use and Health (NSDUH) is an annual survey of the US
population with the purpose of collecting information and identifying trends of behavioral health
in citizens 12 years and older. In 2016, NSDUH identified 44.7 million adults over the age of 18
as having a mental illness, accounting for 18.3% of the total population. NSDUH also found that
10.4 million adults had a SMI within the past year (4.2%). The number of adults with mental
illness in the population remained stable from 2008 to 2016. Mental illness had a higher
prevalence among adults 26 to 49 years old (21.1%) and 18 to 25 years old (22.1%) compared to
adults aged 50 or older (14.5%).5

Mental illness results in a high economic burden due to its debilitating effect on the patient’s
capacity to function. Therefore, unlike other common medical conditions, mental illness has
higher indirect costs than direct costs. Notable indirect costs include reduced labor force
participation, caregiver burden, public disability supplementation, and costs associated with
imprisonment and homelessness. The annual loss of earnings alone is estimated to be $193.2
billion per year.6 When combining indirect and direct costs, mental illness is estimated to cost
the US approximately $317 billion per year, or more than $1,000 per capita.7

Mental illness has an impact on patient’s functioning ability due to its effect on basic activities of
daily living, interpersonal relationships, and the ability to function in the workplace. According
to the WHO, mental and behavioral disorders account for 13.6% of the total US disability-
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adjusted life years (DALYs), ranked third in DALYs in the US, only behind cardiovascular and
circulatory disorders and neoplasms.8 In study of global burden of diseases by Gore et al.,
researchers concluded that 45% of all DALYs of youth between 10 and 24 years old were
attributed to psychiatric disorders.9 It is estimated that there are currently 165,000 homeless
people in the US who suffer from a serious mental illness.10 The debilitating nature of the
disease may play a role in this high prevalence rate. The high level of DALYs and rate of
homelessness in mentally ill patients shows that not only is mental illness highly prevalent, but
also has a significant impact on the functioning ability of those who are affected by it.

b. Diagnosis
The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) is the
classification and diagnostic tool used by healthcare professionals worldwide to diagnose a
clinical mental disorder. The goal of the DSM-5 is to ensure that clinicians can accurately and
consistently diagnose patients with mental illness. The DSM is reviewed and revised periodically
by the American Psychiatric Association (APA) to adjust to new advances and discoveries in
mental health research. The current 5th edition was published in 2013.11 The DSM-5 is often used
to make decisions regarding treatment plans and payments, therefore it provides a uniform tool
for healthcare professionals to use to avoid variability that may have a negative impact on the
patient.

In addition to DSM-5, other mental health assessment tools are utilized during the mental illness
diagnosis process in order to enable an earlier identification of the disease and prevent a
misdiagnosis, therefore, leading to a more effective treatment plan. They also provide medical

3

professionals with a common objective metric that can assure a consistency in diagnoses.
Although a medical professional is needed to make a clinical diagnosis, these tools also assist
patients with a quick, easy, and low-cost way to determine if they are experiencing mental illness
symptoms. Mental health assessments tools can be used as general mental health screening tools
or can be disorder specific severity measures.12

c. Etiology and risk factors
The exact causation of mental illness is complex and fluctuates from condition to condition. Risk
factors for the development of mental illnesses include genetics, environmental factors, social
influences, and illicit drug use.

Multiple studies have indicated that genetic factors play a role in the development of mental
illness. Sellers et al. conducted a longitudinal study to assess if a mother's recurrent depression
predicted new-onset psychopathology in their children.13 The study found that the number of cooccurring mental illnesses in the mother (0, 1, or 2+) predicted new-onset offspring disorders
(OR = 1.80, 95% CI 1.17–2.77, p = 0.007), therefore concluding an increased risk of future onset
psychiatric disorders in offspring from pre-existing mental illness.13 Another study conducted by
Singh et al. set out to assess the link between genetics and mental illness by administering
structured interviews among twins, their spouses, and their children; this demonstrated an
association between parental and offspring depression (HR 1.52, CI 1.20–3.93, p ≤ .05). After
controlling for measured covariates such as sex, divorce rate, and education level, this
association was found to be due to shared genetic liability.14
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Studies have also shown mental illness to be linked to environmental factors surrounding
pregnancy and birth. A population study done in the UK by Dorrington et al. found an
association between psychosis in offspring and the mother experiencing stressful life events
while pregnant (OR = 1.10, CI 1.02–1.18, p ≤.05).15 A wide variety of other prenatal
environmental conditions and stressors are correlated with mental illness such as fetal hypoxia,16
maternal infections,17 maternal exposure to influenza18 and maternal malnutrition.19

Social influences and external factors have been shown to have an effect on the development and
severity of mental illness in those who are genetically and biologically vulnerable to mental
illness. Recent studies have linked the development of mental illness to sexual abuse,20 physical
abuse,21 emotional abuse,22 domestic violence23 and bullying.24 Childhood trauma such as poor
parenting and neglect has been found to be a risk factor for both depression and anxiety.25,26

Substance abuse, especially long-term use, can increase the risk of mental illness. Heavy alcohol
use or dependence has been linked to major depressive disorder.27 Heavy marijuana use,
especially at a young age, has been linked to depression and anxiety.28 Marijuana users are at
double the risk of having a psychotic episode or developing long-term schizophrenia, and
children who use marijuana at before the age of 20 have a higher risk of developing bipolar
disorder.29 The use of drugs such as cocaine and amphetamines have been found to put an
individual at a higher risk of developing schizophrenia.30
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d. Treatment modalities
There are different methods to treat mental illness, with the most effective treatment plans being
the ones tailored to patient- and condition-specific needs. A variety of different healthcare
professionals can provide mental health treatment such as primary care physicians, psychiatrists,
psychiatric health nurse practitioners, clinical psychologists, psychiatric pharmacists, and social
workers. Facilities that provide mental illness treatments include hospitals, clinics, and a variety
of different community mental health services. Mental illness is typically treated through a
combination of psychotropic medications and psychotherapies but other complementary
treatment modalities can be added to a patient’s care plan.31

Psychotropic medications play a key role in the treatment of mental illness. The five main
psychotropic categories are antidepressants for depression, anti-anxiety or anxiolytics for anxiety
disorders, antipsychotics for psychosis disorders such as posttraumatic stress disorder (PTSD),
obsessive-compulsive disorder (OCD) and schizophrenia, mood stabilizers for bipolar disorder,
and stimulants for attention deficit disorders (ADD).32 If taken as prescribed, psychotropic
medications have been shown to be efficacious in treating mental illness. In a meta-analytic
study of the short-term efficacy of antidepressants versus a placebo, Storosum et al. found
significant decrease in symptom severity using the Hamilton Depression Rating Scale.33 Another
meta-analysis conducted by Barbui et al. concluded that paroxetine, a selective serotonin
reuptake inhibitor (SSRI), was more effective than placebo in increasing the amount of patients
who experienced improvement in at least half of their symptoms (RR 0.83, 99% CI 0.77–0.90).34
The mood stabilizer lithium has been found to be highly effective in treating bipolar disorder,
reducing the frequency of symptom relapse by 50% (Hedges- Olkin effect size =0.68, CI =0.60-
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0.76).35 While a majority of studies show psychotropic medications to be efficacious, their
outcomes may vary due to factors such as disease severity, duration of disease, and
comorbidities.

Psychotherapy refers to a variety of treatment techniques that aim to help a patient overcome the
negative effects of the mental illness they are struggling with. Through psychotherapy, a
psychologist helps the patient understand their condition and develop healthier and more
effective habits of coping with the condition. There are different types of psychotherapies
including cognitive behavioral therapy, interpersonal therapy, family therapy, and condition
specific therapies.36 Of the types of psychotherapies, cognitive behavioral therapy (CBT) is the
most commonly used in the treatment of mental illness. CBT is short-term and talk-centered
psychotherapy that aims to improve the patient’s underlying thoughts and actions that result in
negative experiences. CBT helps improve the patient’s cognitive processes by changing their
current thoughts, personal images, beliefs, and attitudes in regard to their emotional problems.
CBT is especially effective in the mental illness population due to its focus on teaching patients
coping skills and how to apply these skills to their current situation. Those with mental illness
experience a decrease in functioning ability and have a higher need for the development of
coping skills. For example, a patient with major depressive disorder (MDD) may learn how to
pay more attention to their negative thoughts and approach them with a more realistic analysis
therefore preventing the patients from experiencing a decrease in mood. CBT is also effective for
mental illness treatment due to its focus on improving one’s self-beliefs. For example, mental
illness patients may feel inferior, mentally flawed, or stigmatized by others. CBT helps patients
dispel those beliefs and accept oneself for who they are.37
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Along with psychotherapy and medications, a patient with mental illness may also consider other
treatment options to supplement their care plans. Lifestyle changes such as dietary adjustments,
gainful employment, stress reduction, and peer support have been showed to help decrease
symptoms in certain conditions such as depression and anxiety.38 Non-clinical interventions have
also been shown to be effective treatment options. A study by Talwar et al. found that a
combination of music therapy plus standard care can reduce symptom severity in patients with
schizophrenia when compared to standard care alone.39 Yoga has also been found to improve the
symptoms of mental disorders. In a meta-analysis conducted by Klatte et al., body-oriented yoga
was found to lower a patient’s mental illness symptom severity (Hedges' g = 0.91; 95%
confidence interval 0.55-1.28).40 In rare cases, psychosurgery treatments can be utilized such as
transcranial magnetic stimulation, vagal nerve stimulation, stem cell therapy, deep brain
stimulation, and electroconvulsive therapy.41,42

e. Specific mental illness conditions
i. Major depressive disorder
Major depressive disorder (MDD), commonly referred to as clinical depression, is the most
common mental illness in the US. MDD negatively affects one’s emotions, thoughts, and actions
causing the patient to be in a state of sadness and disinterest. Characteristics of MDD include
depressed mood, loss of interest in activities, changes in appetite, trouble sleeping, fatigue,
restlessness, decreased concentration, and thoughts of suicide.43 In the Global Burden of Disease
Study of 2013, approximately 253 million people or 3.6% of the global population were found to
be affected by MDD.44 In 2015, the National Institute of Mental Health (NIMH) estimated that
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16.1 million or 6.7% of the US population aged 19 or older suffer from MDD. MDD accounts
for 3.7% of all US DALYs, the highest among mental disorders.45 The annual cost of illness is
approximately $210.5 billion with 45-47% accounting for direct costs, 48-50% accounting for
loss of productivity, and 5% to suicide-related costs.46

A diagnosis of MDD requires a patient to have a depressed mood or loss of interest in nearly all
normal activities for at least two weeks duration. The patient must also have at least three of the
following symptoms: insomnia or hypersomnia, feelings of worthlessness or excessive guilt,
fatigue or loss of energy, diminished ability to think or concentrate, substantial change in
appetite or weight, psychomotor agitation, and recurrent thoughts of death or suicide.47 Not all
patients with MDD experience the same symptoms. The severity, duration, and frequency of
MDD symptoms vary according to the individual patient and also depend on the stage of the
illness.48 The Patient Health Questionnaire (PHQ-9) is the most commonly used MDD
assessment tool, which consists of ten questions assessing the frequency and severity of the
patient’s MDD symptoms.12

Treatment for MDD utilizes a combination of medication and psychotherapy. Medication options
for patients with MDD include selective serotonin reuptake inhibitors (SSRIs), serotonin
norepinephrine reuptake inhibitors (SNRIs), bupropion tricyclic antidepressants (TCAs), and
monoamine oxidase inhibitors (MAOIs). Medication choice is based on patient preference,
history of prior medication, safety, tolerability, side effects, and cost. Generally, MAOIs are only
prescribed to patients who have not responded to previous medications.49 TCAs and MAOIs are
first generation medications that enhance the body’s serotonin and norepinephrine production
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mechanism but also block histaminic and cholinergic receptors sites therefore resulting in
unwanted medication side effects. SSRIs and SNRIs are new generation antidepressants that
target specific brain receptor sites therefore resulting in less unwanted side effects.50 Lifestyle
changes such as physical activity and diet change are also recommended to help counteract the
symptoms of MDD.51

ii. Generalized anxiety disorder
Anxiety disorders are states of abnormal and excessive nervousness, anxiousness, and fear.
Generalized anxiety disorder (GAD) is a chronic mental illness in which a patient is in a constant
state of worriedness that interferes with his or her daily activities. GAD can also cause physical
symptoms such as restlessness, fatigue, lack of concentration, muscle tension, and problems
sleeping. Due to the severe symptoms of GAD, patients usually struggle with holding a job or
completing everyday activities.52 Kessler et al. estimated that the lifetime prevalence of GAD in
the US at 4.3% and the twelve-month prevalence at 2.0%.53 In general, GAD is more likely to
affect females than males.54 GAD also has a high economic burden on patients, with a mean
annual direct medical cost for a patient with GAD estimated at $6,475.55

According to the DSM-5, a diagnosis of GAD requires a patient to have excessive anxiety on the
majority of the days for at least six months, difficulty controlling their worrying, and three or
more of the following symptoms; restlessness, fatigue, difficulty concentrating, irritability,
muscle tension, and sleep disturbance.56 A thorough mental health evaluation is essential to a
GAD diagnosis due to the high risk of a misdiagnosis. Anxiety can be brought on by other
physical health conditions such as hyperthyroidism or hypoglycemia. Certain medications may
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result in anxiety as a side-effect. Other untreated mental illnesses such as OCD and MDD can
also increase a patient’s anxiety level.57 The Generalized Anxiety Disorder – 7 item scale (GAD7) is the most commonly used screening tool that helps indicate whether or not a patient requires
a complete clinical assessment for GAD. The GAD-7 assess the frequency of common GAD
symptoms over the past 2 weeks, ranging from symptoms are not present at all to symptoms are
present nearly every day.12

Medications are used to relieve the symptoms of GAD but they do not cure the disorder itself.
Anti-anxiety medications are used to reduce the symptoms of GAD including excessive anxiety,
panic attacks, and extreme fear and worry.57 Benzodiazepines are the first-line anti-anxiety
medications for GAD but should only be used short-term due to their high potential of
dependence and abuse.32 Benzodiazepines treat GAD by inducing relaxation in the patient and
reducing muscular tension. Beta-blockers can be prescribed to help relieve the physical
symptoms of GAD such as rapid heartbeat, shaking, and trembling. Antidepressants have also
been shown to be effective for treating anxiety.57 Stress management, meditation, and support
groups have also been shown to help alleviate the symptoms of GAD.52

iii. Bipolar disorder
Bipolar disorder, sometimes referred to as manic-depressive disorder, is characterized by unusual
and extreme shifts in mood, energy, activity levels, and ability to function in everyday activities.
Patients with bipolar disorder experience shifts in emotional episodes ranging from manic highs
to depressive lows. The side-effects of a manic episode include feeling euphoric, high energy,
trouble sleeping, and exhibiting risky behavior such as spending money or engaging in unsafe
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sexual practices. The side-effects of depressive episodes include extreme sadness, low energy,
over sleeping, anxiety, trouble concentrating, and thoughts of suicide.58 A patient can be
diagnosed as either bipolar I or bipolar II. While both of these diagnoses include similar
depressive episodes, bipolar I patients experience much more severe mania episodes compared to
bipolar II patients. Bipolar II patients experience hypomania, which is a less severe form of
mania that would be considered atypical but not abnormal. Bipolar I patients exhibit manic
behaviors which are more extreme and abnormal.59 In the US adult population, the lifetime
prevalence of bipolar disorder is estimated to be 3.9% and the annual prevalence is 2.6%. Bipolar
disorder is more likely to affect younger patients between 18-29 years old and a lower
prevalence is seen in the older population above the age of 60. The average age-of-onset is 25
years old.60 A systematic review of cost of illness studies for bipolar disorder conducted by
Kleine-Budde et al. found that the cost per capita in the US ranged from $8,000 to $14,000 per
year in direct healthcare costs and $2,000 to $11,000 in indirect costs.61

Bipolar disorder is usually diagnosed in adolescence or early adulthood but can occur at any
age.62 Diagnosing a patient with bipolar disorder is difficult due to the various other mental
illnesses that share similar symptoms such as MDD, substance-induced mood disorder, ADHD,
and conduct disorder.63 Another reason diagnosing is difficult is because a patient is more likely
to seek treatment during a depressive state compared to a maniac state therefore possibly
receiving an inaccurate MDD diagnosis.58 The most common screening tool for bipolar disorder
is the Mood Disorder Questionnaire (MDQ), which consists of 13 questions evaluating the
presence of common symptoms.12 Other measures and rating scales used to evaluate bipolar
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disorder include the General Behavior Inventory (GBI), the Bipolar Spectrum Diagnostic Scale
(BSDS), and the Hypomania Checklist (HCL-32).64

While there is no cure for bipolar disorder, medications are used to control the manic and
depressive episodes. Mood stabilizers help the patient control mood swings by decreasing
abnormal brain activity. Antipsychotics are typically prescribed to help manage the psychosis
caused by the manic phases such as delusions or hallucinations. Antidepressants are used to treat
the depressive phase of bipolar disorder in the same way they are used to treat MDD. A patient
taking medication for bipolar disorder should be heavily monitored by their doctor or pharmacist.
When a patient is experiencing a manic phase, they may believe they do not need to take the
medication and sudden stoppage of bipolar medication leads to worsening of symptoms and in
some cases to potentially fatal withdrawal side-effects.32

iv. Schizophrenia
Schizophrenia is defined as a long-term mental illness characterized by a breakdown of thoughts,
emotions, and behaviors that cause a patient to have a distorted perception of reality, leading to
inappropriate actions and a withdrawal from everyday life. Although schizophrenia is less
prevalent than other mental disorders, it is associated with more severe and debilitating
symptoms. There are three different categories of symptoms that a patient with schizophrenia
experiences: positive symptoms, negative symptoms, and cognitive symptoms. Positive
symptoms are psychiatric behaviors that are not present in those without schizophrenia. These
symptoms include visual or audible hallucinations, delusions, extreme paranoia, and unusual or
dysfunctional thoughts. Negative symptoms are deficits in normal emotional or physical
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processes such as extreme reduction in emotional expression, reduced feeling of pleasure, lack of
speech, lack of motivation, and lack of desire to engage in social relationships. Cognitive
symptoms are deficits impacting the cognitive functioning of the patient. These symptoms
include a poor ability to understand information or make decisions, trouble paying attention, and
poor memory.65

There are currently more than 2.6 million people in the US that suffer from schizophrenia which
reflects 1.1% of the population.65 Of those 2.6 million patients, it is estimated that 40% are
untreated.66 There are significantly more males affected by schizophrenia than females.67
Schizophrenia has a high economic burden due to the disease’s high disability; Chong et al.
estimated the total economic burden for the US at $102 million, with indirect costs responsible
for 50-85% of the total cost of illness.68

Schizophrenia is usually diagnosed when the patient is between 16 and 30 years old but in some
rare cases, children have also been diagnosed with the disease.65 According to the DSM-5, a
diagnosis of schizophrenia requires a patient to have three of the five following symptoms:
delusions, hallucinations, disorganized speech, disorganized or cationic behavior, and negative
symptoms.69 The Brief Psychiatric Rating Scale (BPRS) is a tool used to assess the severity of 18
symptoms that are commonly associated with schizophrenia such as anxiety, grandiosity,
hostility, hallucinations, and emotional withdraw. The BPRS can be used to evaluate if a patient
is schizophrenic or to assess the efficacy of schizophrenia treatment.70
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The causation of schizophrenia is relatively unknown; therefore, the treatment of the disease
focuses on controlling symptoms. Schizophrenia is treated through a combination of
antipsychotics and psychotherapy. Coordinated specialty care (CSC) is a vital part of
schizophrenia treatment due to the severity of the disease. CSC is the integration of typical
medication and psychotherapy treatment with other supplemental treatments such as case
management, family involvement, supported education, and employment services in order to
reduce symptoms and improve the patient’s quality of life.65

II.

Substance Use Disorder
a. Definition, burden and impact

Clinicians classify the level to which patients use illicit drugs or alcohol into three categories;
substance use, substance abuse, and substance use disorder (SUD). The purpose of using these
terms is to help professionals determine the severity of the impact that substance use has on the
user’s ability to function. Substance use refers to the low frequency and irregular use of illicit
drugs. Typically, a person’s life is not significantly impacted by substance use until the pattern
evolves into substance abuse.71

Substance abuse refers to the repeated use of psychoactive substances such as alcohol and illicit
drugs, despite known harmful consequences, one or more times in a twelve-month period that
leads to significant impairment.72,73 The results of substance abuse may include struggling with
home, work, and school obligations, substance-related legal problems, and interpersonal
problems.73 In 2014, 27 million people in the US were identified as illicit drug users, accounting
for 10% of the US population.3
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Substance use disorder (SUD), commonly referred to as drug addiction, is a distinct medical
condition that falls under the mental illness umbrella, but will be discussed as a separate entity in
order to establish a clear distinction. SUD is defined by the DSM-5 as “the recurrent use of
alcohol and/or drugs causing clinically and functionally significant impairment, such as health
problems, disability, and failure to meet major responsibilities at work, school, or home.”74
Substance abuse progresses into SUD when the user develops a tolerance to the drug, uses for an
extended period of time, experiences difficulty stopping or controlling use, and experiences
withdrawal symptoms when not using.73 In 2014, 21.5 million people in the US had a SUD in the
past year, 8.1% of the total population. Of those 21.5 million, 1.3 million were between the ages
of 12 to 17, 5.7 million were between 18 to 25 years old, and 14.5 million were 26 year or older.3

Substance abuse and SUD result in a large economic burden to the US due to lost productivity,
direct healthcare costs, and crime. It is estimated that the annual cost of substance use is more
than $600 billion.75 According to the National Drug Threat Assessment created by the US
Department of Justice’s National Drug Intelligence Center, substance use results in more than
$120 billion per year in lost productivity. This includes reduced labor participation ($49 billion),
loss of productivity due to incarceration ($48 billion), and drug-related deaths ($4 billion).76 An
estimated 67% of current drug users over the age of 18 are employed either part-time or fulltime. Another large societal cost due to drug use are criminal justice costs such as criminal
investigations, prosecutions, incarcerations, and victim costs, estimated at $61 billion annually.77
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Substance abuse often leads to other medical problems therefore resulting in more complications
and a lower quality of life for the patient. The injection of drugs such as heroin, cocaine, and
methamphetamine play a major role in the spread of infection diseases including HIV/AIDS,
hepatitis B, and hepatitis C.78 Injection drug use accounts for roughly 12% of all new AIDS
cases.79 Excessively consuming alcohol damages many vital organs including the brain. Cocaine
and other stimulant use can lead to complications of the heart, respiratory system, nervous
system, and the digestive system. Due to the intoxicating effect of drug use, many users engage
in frequent and unsafe sexual practices, therefore increasing their likelihood of contracting a
sexually transmitted disease.78

b. Diagnosis
According to the DSM-5, a clinical diagnosis of SUD requires a patient to exhibit a minimum of
two of the following symptoms: 1) Overconsumption or consuming more than originally
planned, 2) failure to control one’s use of the substance, 3) spending extended amounts of time
using, 4) failing to fulfill major obligations such as school, work, or home duties, 5) experiencing
cravings for the substance, 6) continued use despite physical and mental health problems, 7)
continued use despite negative effects on social life, 8) using the substance in a dangerous way
such as drinking and driving, 9) withdrawing from regular activities due to use of substance, 10)
building a tolerance to the substance, and 11) experiencing withdraw symptoms.80 A diagnosis of
SUD then can be categorized according to severity level, ranging from mild to severe. A
diagnosis of mild SUD requires the patient to display two or three of the listed symptoms,
moderate requires four to five symptoms, and severe requires six or more symptoms.81
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c. Etiology and risk factors
While it is still uncertain what exactly causes an individual to be prone to substance abuse,
several studies have identified predicting factors. A majority of risk factors for substance abuse
are thought to occur during the user's childhood or adolescence. In a study conducted by
Kilpatrick et al., 4,000 adolescents were interviewed in order to determine risk factors for current
substance abuse. The researchers concluded that children and adolescences who experienced or
witnessed physical, verbal, or sexual abuse were more likely to develop a drug use habit later in
life. The researchers also concluded that children who had a family member with SUD were
more likely to use drugs, suggesting either an environmental or genetic link.82 Another study
conducted by White et al. found that childhood neglect and abuse play a significant role in the
development of substance abuse.83 In a study of 1,760 young adults, Barrett et al. reported that a
child who was raised in a single parent household is more likely to use drugs in their lifetime
when compared to children raised in a two-parent household.84 In regards to alcohol, a study
conducted by Ohannessian et al. found that children with parents who suffer from alcoholism
have a higher predisposition to developing alcoholism later in life when compared to children of
non-alcoholic parents.85 Other factors that increase substance use risk include peer substance use,
drug availability, early aggressive behavior, and low socioeconomic status.86

d. Treatment modalities
As with most mental illnesses, SUD is treated through a patient-tailored combination of
psychological therapy and medication therapy. Initial treatment of acute withdrawal often
includes medical detoxification, which is a set of medical interventions with the purpose of
managing acute intoxication and withdraw symptoms. Through detoxification, harmful toxins in
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the bloodstream are eliminated though dieting, drug abstinence, withdrawal management, and
medications. The most commonly used medications for detoxification are anxiolytics and
methadone.87 Detoxification is not required for certain drugs, including cocaine,
methamphetamine, and marijuana, because the withdraw symptoms are not as severe compared
to other drugs. Certain drugs absolutely require detoxification because the withdrawal symptoms
are so severe that they may be fatal if not properly treated. These drugs include alcohol, heroin
and opioid prescription drugs.88

After detoxification, it is recommended that the patient seeks help from a professional
psychologist to make a treatment plan tailored to their needs with a focus on health, living
situation, the individual’s purpose for quitting, and community support.89 There is currently a
wide range of treatment options available including individual counseling and group counseling,
inpatient and residential treatment, outpatient treatment, hospital programs, recovery support
services, 12-step programs such as Alcoholics Anonymous (AA) or Narcotics Anonymous (NA),
and peer support groups. Cognitive-behavioral therapy has been shown to improve outcomes in
SUD by helping the user recognize factors that lead to their negative behavioral patterns such as
stressors, negative situations, and actions that lead to substance use.90 Motivational interviewing
has also been shown to be effective in implementing behavioral change in those with SUD.91
Along with psychotherapy, the addition of social and family support has been shown to be
critical to helping the patient adhere to their recovery plan.90
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i. Relapse
SUD is a chronic disease and the recovery stage of the disease lasts for the entire duration of the
patient’s life. When a patient with SUD quits using for an extended period of time and then
resumes using again, it is referred to as a relapse. Similar to most chronic diseases, those with
SUD often experience periods of remission and relapse. Relapses are commonly caused by
triggers, or external circumstances that cause the patient emotional or psychiatric distress such as
anxiety, panic, stress, depression or discouragement.92 Triggers can be classified into three
groups: environmental, re-exposure, and stress. Environmental triggers are circumstances that
the patient once associated with drug use such as social events or friends. Re-exposure triggers
are events in which the patient is in the presence of drug use therefore leading the patient back to
their previous drug seeking behavior. Stress triggers are events that cause intense emotional
states such as anger, fear, anxiety, and sadness that lead the patient to returning back to use.93
Experts suggest patients at risk of relapse identify triggers and develop an action plan of what
steps to take when they find themselves in trigger situations.92

e. Specific substance use disorders
i. Alcohol
Of the 21.5 million people with a SUD last year, 17 million (6.4% of the total US population)
had an alcohol use disorder. Alcohol use is broken down into three different categories: current
alcohol use, binge alcohol use, and heavy alcohol use. These are the criteria used by the
Substance Abuse and Mental Health Services Administration (SAHMSA) to categorize the
levels of alcohol use and do not equate to a diagnosis of SUD. Current alcohol use is defined as a
person having any alcoholic drink within the last 30 days. Binge alcohol use is defined as a
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person having five or more drinks or drinking to a point of intoxication at least once in the last
30 days. Heavy alcohol use is defined as drinking five or more drinks or drinking to a point of
intoxication five or more times in the past 30 days. In 2014, 139.7 million people were current
alcohol users, 60.9 million people were binge alcohol users, and 16.3 million were heavy alcohol
users.3 In 2011, Bouchery et al. calculated the economic cost of alcohol consumption in the US
including healthcare costs, productivity losses, and other miscellaneous costs such as property
damage; the total estimated economic costs of excessive drinking were $223.5 billion, with
72.2% in lost productivity, 11% in healthcare costs, 9.4% in criminal justice costs, and 7.5% in
other miscellaneous costs. This cost can be broken down to approximately $746 per person or
$1.90 per alcoholic drink consumed per year.94

ii. Illicit drugs
Of the 21.5 million people with a SUD last year, 7.1 million had an illicit drug use disorder
which represents 2.7% of the total population. An estimated 867,000 of those with illicit drug use
disorder were between 12 and 17 years old, 2.3 million were between 18 and 25 years old, and
3.9 million were 26 years and older.64 The most common illicit drug use disorders in the US are
cannabis use disorder, stimulant use disorder, and opioid use disorder.74 While there are many
other SUDs prevalent in the population, the following three SUDs will be focused on because
they are the most common in the US.

1. Marijuana
Marijuana is currently the most used illicit drug in the US. In 2014, 22.2 million people reported
using marijuana within the last month, and 4.2 million met the criteria for a SUD based on their
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marijuana use alone.95 The short-term effects of marijuana include distorted perception,
difficulty thinking and problem solving, and reduced motor skill coordination. The symptoms of
cannabis use disorder include tolerance to the drug, drug cravings, difficulty sleeping, anxiety,
anger, and depression. Long-term use has been proven to cause respiratory infection, impaired
memory, and cancer. Early age marijuana use has also been linked to mental illness and poor
cognitive functioning.74

2. Stimulants
Stimulants are drugs that increase alertness, attention, and energy, and have a high potential for
abuse due to the euphoric state the user experiences. The term stimulants can refer to prescription
medications such as methylphenidate or illicit drugs such as amphetamines, methamphetamines,
and cocaine. In 2014, 1.6 million people were current nonmedical users of non-cocaine
stimulants, of which 569,000 were current users of methamphetamine. It is estimated that 1.5
million people are current cocaine users of which 913,000 have a current cocaine use disorder.3
Symptoms of stimulant use include drug cravings, loss of control of use, tolerance, high blood
pressure, increased heart rate and respiration. The withdraw symptoms of stimulants include
fatigue, trouble sleeping, increased appetite, and irregular or spastic movements.74

3. Opioids
Opioid use and abuse is currently a nationwide problem that is severely impacting the health,
social, and economic state of the US. Opioid abuse can refer to the use of prescribed painkillers
such as hydrocodone, oxycodone, morphine, and codeine in a manner that does not coincide with
a physician’s directions. Prescription opioids are prescribed to reduce a patient’s pain but may be
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taken recreationally due to the intense high and euphoria they induce. Opioid abuse can also
occur when the patient takes the medication for pain but not according to physician
recommendations. In 2014, it was estimated that 4.3 million Americans used a prescription
opioid for nonmedical purpose and 1.9 million had an opioid use disorder due to prescription
opioids.96 In 2014, there were nearly 18,000 reported deaths due to prescription opioids, a 3.4fold increase from 2001.97 The most common drugs responsible for overdoses are methadone,
oxycodone, and hydrocodone.98 Experts contribute the severity of the problem to the increase in
number of opioids prescribed by physicians, which has increased from 76 million in 1991 to 207
million in 2013. The US is the largest consumer of opioid drugs, prescribing nearly 100% of the
world total of hydrocodone and 81% of the world total of oxycodone.99 Over the past few
decades, the U.S. Food and Drug Administration (FDA) has made a priority of solving the
problems of opioid misuse, abuse, and addiction by targeting and improving drug development,
drug packaging and labeling, prescriber and patient education, and addiction treatment efforts.100

In addition to prescription drugs, opioid abuse can also refer to the use of illicit substances such
as heroin, a powerful and lethal opiate synthesized from morphine. Many heroin users misuse
prescription opioids and then progress to using heroin due to the substantial cost difference. The
side effects of heroin use include an intense euphoria, drowsiness, respiratory depression, and
nausea. Symptoms of a heroin overdose include trouble breathing, blue lips and fingernails,
uncontrollable sweating, convulsions, coma, and death.96 In 2014, there were 435,000 people in
the US who have used heroin in the past month and 586,000 had a heroin use disorder.3 It is
estimated that 4.8 million people have used heroin in their lifetime.96 There were more than
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10,000 deaths involving heroin in the US in 2014, which accounts for a 6-fold increase from
2001.97

III.

Dual diagnosis
a. Definition, burden and impact

Dual diagnosis is the co-occurrence of a mental illness and SUD. Patients with dual diagnosis
exhibit more persistent, severe, chronic, and treatment-resistant symptoms when compared to
patients with SUD or a mental illness alone. The presence of a dual diagnosis in a patient results
in more severe negative health outcomes such as relapse of psychiatric illness, hospitalization,
disruptive behavior, family stress, homelessness, legal problems, decreased functioning status,
HIV infections, and low medication adherence.101

In 2014, it was estimated that 7.9 million adults had a dual diagnosis, representing 39.1% of the
total SUD population, 18.2% of persons with mental illness, and 3.3% of the total US population.
It is estimated that there are currently 2.3 million adults (1.0% of the US population) with a
serious mental illness and SUD. Of the 7.9 million dually diagnosed patients, 36.0% were
between the aged of 18 and 25 years, 42.7% were between 26 and 49 years, and 35.6% were 50
or older.3

b. Diagnosis
Accurately diagnosing a patient with a dual diagnosis has been proven to be difficult for
physicians. Dual diagnosis is currently not a distinct diagnosis in the DSM-5, therefore there is
no standardized diagnosis criteria that can assist physicians to make a proper diagnosis.102
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Diagnosis is further complicated with symptoms of substance abuse and acute withdrawal being
similar to mental illness symptoms. Withdrawal from alcohol in most cases causes patients to
exhibit symptoms of depression, and psychedelic drugs cause patients to display symptoms
similar to schizophrenia and psychosis. Withdrawal from stimulants cause extreme anxiety in
their users. For a patient to truly have a dual diagnosis, the mental illness must still be present in
the absence of drug use or after acute withdrawal has taken place, or must have been present
prior to establishment of the substance use disorder. Therefore comorbid SUD and mental illness
has been problematic to accurately diagnose.103

c. Etiology and theories of development
Despite the high prevalence and severity of dual diagnosis, little is known as to why the cooccurrence of these two diseases happens but there are some theories established by previous
research. The highly debated causality theory states that heavy and long-term drug use leads to
the development of mental illness. For example, a study conducted by Moore et al. concluded
there was an increased risk of a psychotic event in those who have used cannabis compared to
those who have not (adjusted OR =1.41, 95% CI 1.20–1.65, p=0.28). Moore et al. also found a
dose-response effect, there was an increased risk of a psychotic event in those who used cannabis
more frequently compared to those who used less frequently (adjusted OR=2.09, 1.54–2.84;
p=0.11).104 Other studies have also shown that use of stimulants and hallucinogens can lead to
long-term psychotic disorders such as schizophrenia or affective disorder.105

Another theory to explain the high co-occurrence of these disorders is the self-medicating theory.
Patients with mental illness may be in a state of constant discomfort in which the use of illicit
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drugs helps alleviate. The presence of a mental illness may cause a patient to experience extreme
emotional highs and lows, and the use of illicit drugs may result in temporary alleviation of these
feelings or give the patient a perceived control over them.106 A patient receiving treatment for
their mental illness may also use illicit drugs to regulate the side effects of psychotropic
medications. For example, a frequent side effect of antipsychotic medications is sedation and
lack of energy therefore patients may use stimulants such as amphetamines to counteract the
sedation.107 There are currently multiple diagnostic studies that both support and reject the selfmedicating theory.106

Another theory used to explain dual diagnosis is the alleviation of dysphoria theory. Dysphoria is
a state of severe unease or dissatisfaction and is often experienced by those with depression and
anxiety disorders. The theory states that patients with dysphoria are more likely to engage in
illicit drug use to alleviate these feelings.107 In a study conducted on a cohort of inpatients with
schizophrenia, it was found that patients with an alcohol-related diagnosis were more likely to
cite alcohol use as a relief to their problems and worries.108

The overlapping risk factors theory attempts to explain the co-occurrence of SUD and mental
illness by crediting the high prevalence to the multiple overlapping risk factors for each disease.
These factors include social isolation, low socioeconomic status, lack of adult role responsibility,
lack of structured daily activity, and living in areas with high drug availability. There is also
evidence that experiencing traumatic life events such as sexual or physical abuse can put a
person at a higher risk for both mental illness and SUD.107
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Lastly, the super sensitivity theory states that patients with mental illness also have biological
and psychological vulnerabilities caused by genetic and environmental factors that make it more
difficult to cope with negative or stressful life events. For example, a patient with major
depressive disorder will not be able to deal with the loss of a love one as well as someone
without a mental illness. Therefore, these individuals may not have the capability of sustaining
moderate drug use and also be more likely to experience the negative consequences of illicit drug
use such as addiction. The super sensitivity theory also provides an explanation to why patients
with a mental illness often experience the negative consequences of drug use even while using
relatively low levels of the substance.107

d. Treatment modalities
The dual diagnosis population often requires intense and patient-specific treatment due to the
complexity and severity of their disease. There are many barriers to treatment for those with dual
diagnosis and according to the 2015 National Survey on Drug Use and Health only 6.8% of those
with a dual diagnosis received treatment for both their mental illness and SUD.109 While it is not
completely clear why there is a lack of dual diagnosis specific treatment, some researchers
conclude that it may be due to dual diagnosis patients being more difficult to work with, more
likely to be noncompliant to treatment plans, less responsive to typical treatment, and more at
risk of violence.110 A majority of previous research concludes that combining both mental illness
and SUD treatment into a single care plan is the most effective way of treating dual diagnosis
patients. In a literature review conducted by Drake et al., 26 controlled studies of dual diagnosis
psychosocial therapy were observed and the most effective treatments were the mental illness
and SUD integrated interventions that focused on individualized personal factors.111
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IV.

Medication adherence
a. Definition, burden and impact

The WHO defines adherence as "the extent to which a person’s behavior – taking medication,
following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations
from a health care provider."112 Although the term is most often used in regards to taking
prescribed medication, it can also refer to numerous other health-related behaviors.112 Adherence
has a high impact on the health of patients due to its correlation with health outcomes. Low
medication adherence can result in adverse effects, increased healthcare costs, patient frustration
with disease and treatment, misdiagnosis, unnecessary treatment, increase in disease severity,
increase in symptom severity, and death.113

It is important to distinguish between the terms adherence and compliance. Until recently, noncompliance was used to describe the degree to which a patient followed the directions given by
their medical providers. The term adherence was then introduced to refer to the extent to which a
patient's health behavior reflects their health plan which was agreed upon by both the clinician
and the patient. Adherence is more patient attitude-centered while compliance is more cliniciancentered. Adherence also acknowledges that the patient plays a role in choosing and following
their health plan and outcomes.114

A patient's non-adherence can be categorized as intentional or unintentional. Intentional nonadherence occurs when a patient deliberately does not take their medications for reasons such as
to save on medication costs, lack of motivation, and belief that the medication is not efficacious.
Unintentional non-adherence occurs when a patient lacks the capacity to follow their regimen.

28

For example, an older patient may forget to take their medications or a patient with multiple
daily medications may not be able to take all as directed.115

Non-adherence can also be categorized as primary or secondary. Primary non-adherence refers to
when a patient is prescribed a medication but fails to fill the prescription. Primary non-adherence
is common among patients receiving new medications. In a study of 195,930 e-prescriptions,
researchers found that only 72% of new prescriptions were ever filled.116 Secondary nonadherence refers to when a patient fills their prescription but does not take the dosage as
recommended. Secondary non-adherence is usually due to patients wanting to save costs,
forgetting to take their medications, or believing their medication is not efficacious.
Interventions designed to improve adherence must determine which type of non-adherence the
patient experiencing in order to effectively improve their behaviors.

In 2003, the WHO concluded that non-adherence is the number one cause of preventable
morbidity, mortality, and healthcare costs.117 It is estimated that the medication adherence rate
across chronic diseases in the US is roughly 50%, therefore out of the 3.2 billion prescriptions
dispensed in the US, 1.6 billion are not taken by the patients to whom they are prescribed. .112,118
In a study conducted by Jackevicius et al., a cohort of patients with acute myocardial infarction
were followed post-hospital discharge and only 74% of the patients filled their prescription after
120 days.119 Another large study conducted by Vrijens et al. found that half of patients who were
prescribed antihypertensive drugs completely stopped taking the medication after a year.120 Each
year there are approximately 125,000 deaths in the US that can be attributed to medication non-
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adherence.121 Of the total medication-related hospital admissions in the US, it is estimated that
between 33% and 69% are due to low adherence.118

Medication non-adherence also results in unnecessary and avoidable healthcare costs. The total
annual cost of non-adherence in the US ranges from $100 billion to $300 billion including both
direct and indirect costs.113 In a study of Medicaid patients with heart failure, patients who were
adherent to their medications had an overall costs 23% lower than those who were not
adherent.122 In another study of Medicaid patients with diabetes, researchers found that for every
10% increase in medication adherence resulted in a decline of 9-29% in total healthcare costs.123
Low medication adherence can also result in an increase in indirect costs such as unnecessary
caregiver costs and lost work productivity.118

b. Risk factors and barriers
Low medication adherence or non-adherence can be attributed to a variety of risk factors and
barriers. Poor health literacy or the lack of patient understanding of their treatment plan and
medication directions attributes to low adherence rates, demonstrating a need for patient-tailored
medication counseling.124

Medication costs have been shown to be a barrier to treatment adherence. The US is currently
one of the leading countries with the highest pharmaceutical medication prices125 and increases
in medication costs to the patient is associated with a decline in medication adherence.126 Almost
75% of Americans believe that their prescription drug costs are unreasonably high and 21% find
it difficult to pay for their prescriptions.127 In the past year, 25% of Americans have stated that
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they or a family member have not filled their medication prescriptions in order to save money.
An estimated 18% reported either cutting their pills in half or skipping a dose in order to save on
medication costs.127

Another factor that may lead to low adherence is the complexity of a patient's treatment regimen.
In a study observing the medication adherence in patients prescribed statins for cardiovascular
diseases, researchers found that a greater number of prescribers, visits to more pharmacies, a
greater number of daily doses, and less refill consolidations were predictors of low medication
adherence.128 Lower dosing frequencies and a lower number of medications a patient was taking
has been found to significantly improve medication adherence.129

Low medication adherence can also be attributed to the patient's cognitive beliefs. According to
the WHO, low medication adherence has been linked to illness-relevant cognitions, perceptions
of disease factors, and treatment beliefs. Other cognitive factors associated with medication
adherence include perceived susceptibility of illness, perceived severity of illness, self-efficacy,
and perceived control over the disease. Other studies have also found that patients will be more
adherent to their medications if it results in a timely and noticeable reduction in symptom
severity.112

c. Measurements
Medication adherence can be measured in multiple ways including direct measures, secondary
database analyses, electronic medication packaging (EMP) devices, pill count, and clinician
assessments and self-reports. Direct adherence measuring refers to the process of measuring the
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medication concentration in a patient's bodily fluids such as their blood or urine. While direct
measures are the most accurate ways to measure a patient's medication adherence, there are some
limitations. First, the results only tell the researcher if the medication is present. There is no way
to measure the pattern or cause of non-adherence. Direct measures are very intrusive and require
full cooperation of the patient. Direct measures are the most expensive adherence measurement
techniques and require scientific professionals to conduct the testing.130

Secondary database analysis adherence measurement is the process of accurately estimating a
patient's adherence levels by observing data patterns from databases such as claims databases
and electronic prescription services. This method assumes that the patient's prescription refilling
pattern corresponds with their medication-taking behavior. There are three types of secondary
database analysis adherence measures: continuous variable analysis, dichotomous variable
analysis, and consumption. Continuous variable analysis observes the patient's adherence
behavior from the first prescription to the last prescription on record. An example of this method
is the medication possession ratio (MPR). This method is a simple calculation of the percentage
of days the patient received their medication over the total prescription period. MPR usually
overestimates adherence due to its inability to adjust for gaps in refills. Dichotomous variable
measurements label a patient as either adherent or nonadherent based on some set criteria. This
method is the least used method and has a lower sensitivity due to the lack of a professional
consensus of how to determine the cutoff point. Lastly, the consumption method examines the
time between prescription refills from the perspective of gaps or periods of non-adherence.
Examples of this method includes continuous multiple interval medication acquisition (CMA),
continuous multiple interval medication gaps (CMG), continuous single interval medication
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acquisition (CSA), and continuous single interval medication gap (CSG). CMA calculates
adherence by observing the cumulative days of medication supply obtained over a series of
intervals divided by the total number of days. CMG measures adherence by dividing the total
number of days in treatment gaps by the total number of days. CSA measures the days of supply
obtained in each interval over the total number of days in each interval. CSG is calculated by the
number of days without any medication over the total number of days in the interval.130

Medication adherence levels can also be measured using electronic medication packaging (EMP)
devices. These devices are incorporated into the packaging of the medication and records doses
taken, provides patients audio or visual reminders to take a dose, and gives feedback on the
patient's adherence.130 While EMPs are a highly accurate method of measuring adherence, they
are rarely used in research due to their high cost and the complex support required for use. In a
study on adherence in patients with schizophrenia, the researchers estimated a total cost of $274
per patient to use the devices. The authors also encountered other barriers to use such as
encouraging patients to use the devices correctly and coordinating refills with pharmacies.131

Pill counting is an indirect measure of adherence in which the number of pills left in a patient's
prescription container is counted when they are due for a refill. This number is then divided by
the total number of pills received to calculate an adherence ratio. This method is the least costly
and most simplistic form of medication adherence measurement but includes several limitations.
If a patient does not want to appear nonadherent, they may discard excess medication before
refilling. This method also overestimates adherence due to the inability to determine if patients
over consumed their medications.130
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Medication adherence can be measured through clinician assessments and self-reports. This
method is the most commonly used form of medication adherence measurement in research due
to its relatively low cost, simplicity, and real-time feedback. Medication adherence can be
assessed through an interview in which patients are asked to estimate their adherence rate, how
many medication dosages they have missed, and the reasons to why they believe they are not
adherent. A more structured form of adherence measurement can be done through the use of
standardized or condition specific questionnaires and scales. While there is no gold standard
measure for medication adherence, a commonly used adherence measurement is the 8-item
Morisky Medication Adherence Scale (MMAS-8), which consists of seven yes or no questions
related to medication adherence and one Likert scale type question/statement related to the
frequency of the patient forgetting to take medication.132 There are multiple limitations to using
clinician assessments and self-reporting. Patients may purposely provide false information to
appear more adherent to their medication regimes. There is also a chance for recall bias, in which
patients may not be able to remember the extent to their adherence. The researcher must properly
decide which measurement to use that will most accurately measure the adherence level in their
chosen population.130

d. Adherence in the mental illness population
Medication adherence plays a vital role in the treatment of mental illness. As stated,
nonadherence often results in poor health outcomes, unnecessary costs, increased symptom
severity, and treatment failure, especially in the mentally ill population. In regard to MDD, a
retrospective chart review conducted by Sawada et al. found that 55.7% of patients with MDD
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discontinue their antidepressant medication regimen within the first six months. In the same
study, 55.6% of patients were found to be adherent with a MPR ≥ 0.8.133 In a retrospective,
observational study using medical and pharmacy claims, Akincigil et al. assessed the adherence
rates of 4,312 patients with MDD. The researchers found that 51% of the patients were adherent
during the first 16 weeks of treatment but only 42% remained adherent within 17 to 33 weeks
after the treatment began.134 In a retrospective study of 22,947 patients receiving a SSRI for
MDD, Cantrell et al. found that approximately 57% of the patients were not adherent to their
medication.135

In regard to GAD, medication adherence is essential to controlling a patient’s symptoms,
especially at the early stages of the disease. Using data collected from a community health
survey, Bullock et al. estimated the non-adherence rate of patients prescribed anxiolytics to be
38.1%.136 The current literature on anxiety disorder adherence rates is limited, therefore further
research in the area is needed in order to establish accurate estimates of general adherence rates.

For bipolar disorder, medication adherence is a critical part of controlling the extreme highs and
lows of the disease. A literature review conducted by Lingam et al. observed studies that
measured the medication adherence rates of bipolar disorder patients. The non-adherence rates
were found to range from 20% to 60% with a median non-adherence rate of 41%. 81 In another
large study of 140 patients receiving the mood stabilizers for bipolar disorder, Keck et al. found
that 51% of the patients were non-adherent during the one year follow-up.137
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Medication adherence helps prevent patients with schizophrenia from relapsing back into a
psychotic state. The rate of relapse in schizophrenia patients who are nonadherent is 55%, which
is significantly higher than the relapse rate of 14% for those who are adherent.138 In a study of
100 who were patients hospitalized for acute mania, Keck et al. found that 64% of the patients
were non-adherent to their medication the month before admission.139

e. Adherence in the dual diagnosis population
Due to the complications related to both diseases, the dual diagnosis population experiences
unique barriers to medication adherence. Multiple studies have concluded that substance abuse is
associated with poor medication adherence in patients with mental illnesses.140-142 Evidence
shows this correlation may due to a variety of factors. Substance users often lead a disorganized
lifestyle that may be intensified by a mental illness therefore resulting in difficulty following a
regimented medication schedule. Both mental illnesses and drug use can also impair the
cognitive functioning ability of the patient resulting in impaired judgment regarding medical
behaviors.143 As previously stated, the mentally ill patient may be taking illicit drugs instead of
psychotropic medications as a form of self-medication in order to subdue the side effects of the
disease faster than their prescribed medications. A dual diagnosis patient may attribute their
mental illness symptoms solely to drug use, and therefore not feel the need to take medications.
The risk of non-adherence to psychotropic medication is also high due to their high risk of
adverse events. Low adherence or sudden stopping of the medication may lead to withdraw and
an increase in symptom severity, therefore leading the patient back to their drug use
tendencies.144 Lastly, SUD patients may feel a stigma surrounding their mental illness
medications, as the medication can still been seen as taking "drugs" 143 It is important to
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recognize and treat the factors of non-adherence in the dual diagnosis population because low
medication adherence is associated with negative health outcomes such as re-hospitalization,
homelessness, and lower quality of life.145 Currently, there is limited literature on the adherence
rates of the dual diagnosis population and the affects psychotropic medication adherence has on
the health outcomes of SUD.

V.

Problem Statement

Poor medication adherence is associated with negative health outcomes, especially in patients
with mental illness and substance use disorder. Currently, there is an incomplete understanding
of how medication adherence to psychotropics affects health outcomes of substance use
(relapse). SUD and mental illness are two widely co-prevalent conditions with a poor
understanding of how one affects the other. Further data on the role that medication adherence
plays on SUD outcomes could help interventions target patients more effectively through
specific treatment tailoring and therefore improve health outcomes of this vulnerable and
stigmatized population.

VI.

Hypothesis

The overall hypothesis of the study is that patients with low self-reported adherence rates,
negative attitudes toward their medications, and higher severity of mental illness symptoms will
have significantly higher relapse rates of substance abuse.
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VII.

Research Objectives
a. Research Objective 1: Identify personal, social, and clinical history for patients
with substance use disorder and either major depressive disorder, bipolar disorder,
schizophrenia, or generalized anxiety disorder
b. Research Objective 2: Measure agreeance between patient self-report versus
facility record history for mental illness, substance abuse, and psychotropic
medication
c. Research Objective 3: Investigate the specific role of medication adherence and
barriers to use for psychotropic medications upon substance abuse relapse
d. Research Objective 4: Assess follow-up changes in mental illness severity and
medication adherence in dual diagnosis patients enrolled in a substance abuse
rehabilitation program
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CHAPTER 2 – LITERATURE REVIEW
I.

Introduction
a. Rationale

Patients with dual diagnosis, the co-morbid diagnosis of SUD and mental illness, exhibit more
persistent, severe, chronic, and treatment resistant symptoms than patients with substance abuse
disorder or a mental illness alone. Due to the severity of the disease, patients with dual diagnosis
require unique and personalized interventions in order to improve health outcomes. The primary
goal of interventions for patients with a substance use disorder is the avoidance of relapse, which
is a vital health outcome of dual diagnosis treatment due to the negative consequences associated
with substance abuse relapse.

Poor medication adherence is associated with negative health outcomes in many chronic diseases
including the dual diagnosis population. Patients with mental illness are at a higher risk of
nonadherence due to their lack of awareness of the disease and the significant side effects of
psychotropic medication. Patients with SUD are at a high risk of nonadherence due to the
interaction between illicit drugs and psychotropics, the patient’s lifestyle choices, the effect of
drug use on memory, and self-medication with illicit drugs. The combination of both a mental
illness and a substance use disorder diagnosis only amplifies the risk of nonadherence therefore
leading to poor health outcomes. Therefore, it would be assumed that medication adherence
would be an important focus of dual diagnosis treatment yet there is currently an incomplete
research understanding of exactly how medication adherence to psychotropic medications
impacts the therapeutic outcomes of patients with dual diagnosis, especially substance use
relapse.
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b. Objectives
The objectives of the literature review were to: (1) identify published studies that evaluate the
relationship between substance abuse, psychotropic medications, and medication adherence, and
(2) identify gaps in the existing literature.

II.

Methods
a. Search strategy

The systematic literature review was conducted according to the Preferred Reported Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Peer-reviewed journals were
assessed using the electronic databases PubMed (1996-present), SCOPUS (1990-present), and
PsychINFO (2001-present). The last search was run on March 1st, 2017. Articles that were not
available online were requested and received through the Duquesne University Gumberg
Library. Article eligibility assessment was performed independently by one reviewer and
uncertainty in regard to an article’s eligibility was resolved by a consensus between the reviewer
and the thesis committee chair. A data extraction sheet was developed using Microsoft Excel
(Redmond, WA), including the following from each article: (1) study objectives, (2) year
published, (3) study population characteristics, (4) study location, (5) methodology, (6) relevant
outcomes, (7) self-reported limitations.
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b. Eligibility criteria
The inclusion criteria for the literature review were primary research articles assessing the
relationship between substance abuse, psychotropic medications, and adherence. Review articles,
grey literature, and non-English articles were excluded.

c. Search terms
The search terms used for the PubMED search were as follows:
(Antipsychotic[tiab] OR Antipsychotics[tiab] OR Neuroleptic[tiab] OR Neuroleptics[tiab]
OR Psychotropic[tiab] OR Psychotropics[tiab] OR Antischizophrenic[tiab] OR
Antidepressant[tiab] OR Antianxiety[tiab] OR "Antipsychotic Agents" [Pharmacological
Action] OR "Antipsychotic Agents"[Mesh]) AND (“Drug Dependence”[tiab] OR “Drug
Addiction”[tiab] OR “Drug Habituation”[tiab] OR “Substance Use Disorders”[tiab] OR
“Substance Use Disorder”[tiab] OR “Substance Abuse”[tiab] OR “Substance Abuses”[tiab]
OR “Substance Dependence”[tiab] OR “Substance Addiction”[tiab] OR “Drug Abuse”[tiab]
OR “Drug Use Disorders”[tiab] OR “Drug Use Disorder”[tiab] OR "Substance-related
disorders"[MH]) AND (Adherence[tiab] OR Non-Compliance[tiab] OR
Noncompliance[tiab] OR Non-adherence[tiab] OR Nonadherence[tiab] OR "Patient
Compliance"[Mesh:NoExp] OR "Medication Adherence"[Mesh])

The search terms used for the SCOPUS search were as follows:
TITLE-ABS-KEY (Antipsychotic OR Antipsychotics OR Neuroleptic OR Neuroleptics OR
Psychotropic OR Psychotropics OR "Antipsychotic Agents" OR "Antipsychotic Agents”)
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AND TITLE-ABS-KEY (“Drug Dependence” OR “Drug Addiction” OR “Drug
Habituation” OR “Substance Use Disorders” OR “Substance Use Disorder” OR “Substance
Abuse” OR “Substance Abuses” OR “Substance Dependence” OR “Substance Addiction”
OR “Drug Abuse” OR “Drug Use Disorders” OR “Drug Use Disorder” OR "SUBSTANCERELATED DISORDERS”) AND TITLE-ABS-KEY (Adherence OR Non-Compliance OR
Noncompliance OR Non-adherence OR Nonadherence OR "Patient Compliance” OR
"Medication Adherence”)

The search terms for the PsycINFO search were as follows:
(DE "Neuroleptic Drugs") AND (DE "Drug Abuse" OR DE "Alcohol Abuse" OR DE "Drug
Dependency" OR DE "Inhalant Abuse" OR DE "Polydrug Abuse" OR DE "Drug Addiction"
OR DE "Heroin Addiction" OR DE "Substance Use Disorder") AND (DE "Treatment
Compliance")
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III.

Results
a. Study selection

The results of the search are shown in the PRISMA flowchart depicted in Figure 1.

Identification

Figure 1: Results of the Literature Search

Articles identified through
PubMed database
(n = 366)

Records identified through
SCOPUS database
(n = 830)

Records identified through
PsychINFO database
(n = 11)

Eligibility

Screening

Records after duplicates removed
(n = 1207)

Records screened
(n = 1207)

Full-text articles assessed
for eligibility
(n = 382)

Records excluded
(n = 825)

Full-text articles
excluded, with
reasons
Non-English
(n = 77)

Included

Systematic reviews
(n = 254)

Studies included in
qualitative synthesis
(n = 51)
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b. Study characteristics
A total of 51 studies were included in the synthesis of the literature review. The publication dates
of the articles ranged from 1990 to 2017. The largest study contained a sample of 44,026 patients
and the smallest study contained a sample of 42 patients. Methods utilized to collect data
included structured in-person interviews, self-reported questionnaires, mailed surveys, medical
claims database analysis, medical chart reviews, clinical assessments, and randomized clinical
trials.

Of the 51 studies included, 32 were conducted in the US (63%), four in Canada (8%), three in
Spain (6%), two in Ireland (4%) and two in UK (4%). Other countries with a single article (2%
each) included in the review were Germany, Israel, Nigeria, Denmark, Australia, Norway and
Italy. One multi-country study (2%) took place in Spain, UK and Greece.

The review contained studies assessing multiple mental illness populations. Schizophrenia was
the most reported mental illness in the review (20 articles, 40%). Other mental illnesses studied
included bipolar disorder (9, 18%), psychosis (4, 8%), MDD (3, 6%) and post-traumatic stress
disorder (1, 2%). Two studies (4%) observed patients with either schizophrenia or bipolar
disorder. Two studies (4%) assessed patients with psychotic disorders in general and two other
studies (4%) assessed patients with any DSM-IV mental illness. Of the 51 total studies, 8 (16%)
specifically observed the dual diagnosis population.
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c. Results of individual studies
A summary of studies identified by the systematic literature review are in Table 1.
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Table 1: Details of Individual Studies Identified in the Systematic Review
Authors, Year

Akincigil A, Bowblis
JR, Levin C, Walkup
JT, Jan S, Crystal S
2007 134

Ascher-Svanum H,
Faries D, Zhu B, Ernst
FR, Swartz MS,
Swanson JW 2006 146
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Ascher-Svanum H,
Zhu B, Faries D,
Lacro JP, Dolder CR
2006 147

Baldessarini RJ, Perry
R, Pike J 2008 148

Coldham EL,
Addington J,
Addington D 2002 149

Objective*
To describe patient
and provider level
factors associated
with treatment
adherence in patients
with major
depressive disorder
To examine the
relationship between
adherence to
antipsychotic
medications and
functional outcomes
among schizophrenia
patients
Identify predictors of
nonadherence to
psychotropic
medication in
patients with
schizophrenia
To determine the risk
factors that lead to
nonadherence in
patients with bipolar
disorder
To measure
adherence rates to
antipsychotic
medications in first
episode psychosis
patients

Study Population

Methods

Relevant Outcomes

Limitations

Retrospective,
claims database
analysis

Lower adherence was
associated with alcohol abuse
(OR=0.49) and other substance
abuse (OR=0.72).

Limited
generalizability,
recall bias,
desirability bias

US

Prospective,
interview and
medical record
analysis

Non-adherent patients were
more likely to consume drugs or
alcohol (OR=1.36)

Adherence measure
may be inaccurate

1579 patients in the US
Schizophrenia Care and
Assessment Program

US

Prospective,
interview and
medical record
analysis

Predictors of nonadherence
were illicit drug use 4 weeks
prior to treatment (OR=1.8) and
alcohol use 4 weeks prior to
treatment (OR=1.6)

Not all potential
factors measured

429 adults with bipolar
disorder

US

Cross-sectional,
questionnaire

Alcohol dependence was a
factor significantly associated
with nonadherence (RR=2.26)

Recall bias

Prospective,
interview

Cannabis is a predictor of
nonadherence (OR=0.46).
Alcohol use was significantly
associated with nonadherence
(p=.02)

Recall bias

4312 patients who initiated
antidepressant treatment

1906 participants with
schizophrenia or
schizoaffective or
schizophreniform disorder

200 patients (132 males, 68
females) in the Calgary Early
Psychosis Program with a
first episode of psychosis

Location

US

Canada

Colizzi M, Carra E,
Fraietta S, Lally J,
Quattrone D,
Bonaccorso S,
Mondelli V, Ajnakina
O, Dazzan P, Trotta
A, Sideli L, Kolliakou
A, Gaughran F,
Khondoker M, David
AS, Murray RM,
MacCabe JH, Di Forti
M 2005 150

To clarify the
contribution
substance use and
poor medication
adherence to poor
outcomes after a first
episode of psychosis

205 patients with a first
episode psychosis

Cooper D, Moisan J,
Grégoire J-P 2005 151

To identify
determinants of
compliance among
patients with
schizophrenia

6662 individuals with
schizophrenia initiated on
treatment with atypical
antipsychotics
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Elbogen EB, Swanson
JW, Swartz MS, Van
Dorn R 2005 152

González-Pinto A,
Reed C, Novick D,
Bertsch J, Haro JM.
2010 153

Grunebaum MF,
Weiden PJ, Olfson M
2001 154

To examine the
effect depressive
symptoms and social
stability have on
nonadherence in
psychosis
To identify factors
associated with
medication
adherence in bipolar
disorder patients
To examine the
association between
medication
adherence and level
of supervision along
with other
environmental and
clinical variables

Prospective,
interview and
database analysis

Nonadherence was significantly
associated with nicotine
dependence (OR=2.18),
cannabis use (OR=2.86), and
stimulant use (OR=2.63) but not
problem drinking.

Recall bias, social
desirability

Canada

Prospective,
database analysis

Patients without a history of
substance-use disorder were
more likely to be both persistent
(OR=0.70) and compliant
(OR=0.63) to their medications

Adherence
measurement may be
inaccurate

528 adults with psychotic
disorders receiving treatment
from public mental health
systems

US

Cross-sectional,
interview

Substance abuse was a predictor
for nonadherence (OR=2.04)

Could not establish
temporality

1,831 bipolar disorder
patients either starting or
switching treatment for a
manic/mixed episode

Spain

Prospective,
interview

Nonadherence is associated
with patients with cannabis
abuse/dependence

Adherence
measurement may
not be accurate

74 adult residents with
schizophrenia and related
psychotic disorders living in
supported housing facilities

US

Cross-sectional,
interview

Drug and alcohol abuse was not
associated with adherence

Could not establish
causation

UK

Herbeck DM, Fitek
DJ, Svikis DS,
Montoya ID, Marcus
SC, West JC 2005 155

Hill M, Crumlish N,
Whitty P, Clarke M,
Browne S, Kamali M,
Kinsella A,
Waddington JL,
Larkin C,
O'Callaghan E 2010
156

Hunt GE, Bergen J,
Bashir M 2002 157
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Iasevoli F, Fagiolini A,
Formato MV,
Prinzivalli E,
Giordano S, Balletta
R, De Luca V, de
Bartolomeis A 2017 158

Janssen B, Gaebel W,
Haerter M,
Komaharadi F, Lindel
B, Weinmann S 2006
159

Jónsdóttir H,
Opjordsmoen S,
Birkenaes AB,
Simonsen C, Engh JA,

To examine clinical
and non-clinical
factors associated
with treatment
compliance problems
in patients with
comorbid psychiatric
and substance use
disorders

342 patients with comorbid
psychiatric and substance use
disorders

To examine
associations and
predictors of
nonadherence to
antipsychotics four
years after a first
episode of psychosis

171 patients with a first
episode of psychosis

To examine the
effect of medication
compliance and
substance abuse on
schizophrenia
outcomes
To evaluate the
consistency,
reliability, and
determinants of two
real-world measures
of adherence to
prescription in
schizophrenia
patients
To evaluate patientrelated and
treatment-related
factors associated
with medication
compliance in
inpatients with a
psychotic disorder
To investigate
potential risk factors
for medication nonadherence in patients

US

Cross-sectional,
questionnaire

A comorbid personality
disorder (OR=2.6), lower
functioning ability (OR-3.6), a
current illicit drug problem
(OR=4.0), and medication side
effects (OR=2.5) were strongly
associated with noncompliance

Ireland

Prospective,
interview

Alcohol or drug misuse at
baseline were predictors of
nonadherence at 4 years
(OR=6.9)

Adherence
measurement may be
inaccurate

99 patients with
schizophrenia receiving
acute care in a hospital or a
24-hour community-based
crisis teams

Australia

Prospective,
medical record
analysis

Medication noncompliance
(HR=2.46) and current
substance abuse (HR=1.83)
were predictors of
hospitalization

Limited
generalizability,
small sample size

57 schizophrenia patients and
61 non-schizophrenia
patients

Italy

Cross-sectional,
interview

Substance abuse was a
significant predictor of lower
adherence scores (p=0.027)

Small sample size

670 patients with
schizophrenia,
schizoaffective disorder, or
another psychotic disorder

Germany

Prospective,
interview

Substance abuse was a predictor
for nonadherence (OR=0.52)

Nonrandomized,
adherence
measurement not
validated

Canada

Cross sectional,
clinical
assessments and
blood sampling

A previous diagnosis of
substance abuse or addiction
was associated with
nonadherence in both the

Could not establish
temporality,
Hawthorne effect

255 patients with
schizophrenia or bipolar
disorder

Small sample size,
could not establish
temporality

Ringen PA, Vaskinn
A, Friis S, Sundet K,
Andreassen OA 2013

with schizophrenia
and bipolar disorder

bipolar and schizophrenic
groups

160

To examine factors
related to
noncompliance to
oral antipsychotics in
patients with
schizophrenia

87 patients with
schizophrenia or
schizoaffective disorder
readmitted to a hospital with
acute psychotic relapse

100 patients with a diagnosis
of schizophrenia

162

To identify factors of
first episode
schizophrenia that
predict adherence at
six-month follow-up

Keck PE Jr, McElroy
SL, Strakowski SM,
Bourne ML, West SA.
1997 137

To measure the rates
of noncompliance in
patients with bipolar
disorder

140 patients hospitalized for
bipolar disorder

Krivoy A, Malka L,
Fischel T, Weizman A,
Valevski A 2011 163

To identify the
clinical parameters
that could predict
clozapine
discontinuation in
patients with
schizophrenia

100 patients with
schizophrenia who were
hospitalized and prescribed
clozapine

Lagerberg TVV,
Andreassen OA,
Ringen PAA, Berg
AO, Larsson S, Agartz
I, Sundet K, Melle I.
2010 164

To investigate the
lifetime rates of
substance use in
bipolar disorder
patients and identify
clinical outcome
differences

125 bipolar disorder patients
and 327 population reference

Lang K, Meyers JL,
Korn JR, Lee S,
Sikirica M, Crivera C,
Dirani R, Menzin J
2010 165

To assess adherence
rates and predictors
of nonadherence and
hospitalization
among patients with
schizophrenia

12,032 Florida Medicaid
patients with schizophrenia
receiving a long-acting
injectable and oral
antipsychotic

Kamali M, Kelly L,
Gervin M, Browne S,
Larkin C,
O'Callaghan E 2001
161

Kamali M, Kelly BD,
Clarke M, Browne S,
Gervin M, Kinsella A,
Lane A, Larkin C,
O'Callaghan E 2006
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US

Cross-sectional,
interview

Comorbid substance abuse is a
predictor of noncompliance
(p=.003).

Adherence
measurement may
not be accurate

Ireland

Prospective,
interview

Alcohol misuse and drug
misuse were predictors of nonadherence at six months followup

Low follow-up rate,
compliance
measurements may
not be accurate

US

Prospective,
questionnaire

Noncompliance was
significantly associated
comorbid substance use
disorder

Adherence
measurement may
not be accurate

Israel

Retrospective,
medical record
analysis

Norway

US

Retrospective,
interview

Retrospective,
claims database
analysis

Comorbid substance abuse is a
predictor for drug
discontinuation

Small sample size,
limitations
associated with
retrospective studies

Bipolar patients were
significantly more likely to use
illicit substances compared to
the general population
(OR=3.03). Patients with
excessive substance use had
significantly lower adherence
(p=0.01)

Small sample size,
could not establish
causation

A substance abuse diagnosis is
a predictor of nonadherence
(OR=1.54)

Diagnosis not
verified, adherence
measurement may
not be accurate

Lecomte T, Spidel A,
Leclerc C, MacEwan
GW, Greaves C,
Bentall RP 2008 166

Liu X, Chen Y, Faries
DE 2011 167

Lloyd A, Horan W,
Borgaro SR, Stokes
JM, Pogge DL,
Harvey PD 2009 168

Lockwood A, Steinke
DT, Botts SR 2009 169
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MacEwan JP, Forma
FM, Shafrin J, Hatch
A, Lakdawalla DN,
Lindenmayer JP 2016
170

Magura S, Laudet AB,
Mahmood D,
Rosenblum A, Knight
E 2002 171

Magura S, Mateu PF,
Rosenblum A,
Matusow H, Fong C
2014 172

To assess constructs
that may be linked to
medication
adherence in patients
with early psychosis
To compare
adherence of three
antidepressants and
examine predictors of
adherence in patients
with major
depressive disorder
To determine
predictors of
medication
compliance in
psychiatric patients
To evaluate
adherence and its
effect on relapse
among veterans with
PTSD
To identify patterns
of medication
adherence over time
for patients with
schizophrenia
To examine
associations between
self-help meeting
attendance,
medication
adherence, and
mental health
outcomes in those
with a dual diagnosis
To examine the risk
factors of
nonadherence in
psychiatric patients
with substance
misuse history

118 early psychosis patients

44,026 patients diagnosed
with major depressive
disorder and prescribed an
SSRI

97 adolescent psychiatric
patients

82 veterans diagnosed with
PTSD

29,607 patients with an oral
atypical antipsychotic

240 Double Tree in
Recovery (DTR) self-help
group participants with both
chronic mental illness and a
substance abuse disorder

229 patients with a mental
illness, a history of substance
misuse, and a current
prescription for psychiatric
medication

Limited
generalizability,
adherence
measurement may
not be accurate

Canada

Cross-sectional,
interview

No significant link between
adherence and substance abuse
disorder

US

Retrospective,
claims database
analysis

Alcohol dependence (OR=0.75)
and drug dependence
(OR=0.66) were associated with
decreased adherence

Selection bias,
adherence
measurement may
not be accurate

US

Prospective,
questionnaire

Post discharge substance abuse
is a predictor of nonadherence
(p<0.10)

Participants taken
from previous
substance abuse
study

US

Retrospective,
claims database
analysis

Comorbid substance abuse was
not associated with drug
adherence

Diagnosis not
confirmed,
adherence
measurement may
not be accurate

US

Prospective,
database analysis

Patients with a history of drug
abuse (OR=1.46) and alcohol
abuse (OR=1.34) were more
likely to be less adherent

Potential coding
errors, limited
generalizability

Prospective,
interview

Living in supported housing,
having fewer stressful life
events, and having a lower
severity of psychiatric
symptoms were associated with
adherence

Nonstandardized
measures, adherence
measurement may be
inaccurate

Cross-sectional,
interview

Lower adherence was
associated with medication side
effects, excessive alcohol use,
and a diagnosis of depression.
Schizophrenia was associated
with higher adherence

Limited
generalizability,
could not establish
causation

US

US

Factors correlated with lower
adherence in the substance
misuse population were: lower
social support for quitting
drug/alcohol, lower recoverypromoting behaviors,
nonsatisfaction with
medication, medication side
effects, lower self-efficacy for
drug avoidance, and lower
social support for recovery

Limited
generalizability,
could not establish
causation
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Magura S, Rosenblum
A, Fong C 2011 173

To measure and
determine factors
related to
nonadherence in
psychiatric patients
with substance abuse
histories

131 patients in a psychiatric
continuing day treatment
program who had substance
misuse histories and are
prescribed psychiatric
medication

US

Cross-sectional,
interview

Manwani SG, Szilagyi
KA, Zablotsky B,
Hennen J, Griffin ML,
Weiss RD 2007 174

To examine patterns
of adherence to mood
stabilizers in patients
with bipolar disorder

115 bipolar disorder patients
(58 with SUD and 57 without
SUD)

US

Cross-sectional,
interview

Patients with co-occurring SUD
were less adherent than those
without

Adherence
measurement may be
inaccurate

Miller R, Ream G,
McCormack J,
Gunduz-Bruce H,
Sevy S, Robinson D.
2009 175

To determine if
cannabis use is a risk
factor of
nonadherence

112 first-episode
schizophrenia patients

US

Prospective,
interview

Cannabis use significantly
increased nonadherence
(HR=2.4)

Limited
generalizability, use
of other substances
not observed

Montes JM, Maurino
J, de Dios C, Medina
E 2013 176

Identify factors
associated with
adherence in patients
with bipolar disorder

Spain

Cross-sectional,
interview

Substance abuse/dependence
was a predictor of low treatment
adherence (OR=1.95).

Could not establish
causation, limited
generalizability,
adherence measures
may be inaccurate

50 Patients with bipolar
disorder type I and 75
patients with schizoaffective
disorder, bipolar type

Spain

Cross-sectional,
prospective, and
retrospective,
interview

No association between poor
adherence and substance abuse

Could not establish
causation, limited
generalizability

6731 outpatients with
schizophrenia who were
starting or switching
antipsychotics for clinical
reasons

Spain,
UK,
Greece

Prospective,
interview

Current alcohol dependence
(OR=0.63) and substance abuse
(OR=0.67) were predictors of
nonadherence

Adherence
measurement may be
inaccurate

208 psychiatric out-patients
with psychoactive substance
use in a Nigerian Tertiary
Hospital

Nigeria

Cross-sectional,
interview

No relationship was found
between substance use and
medication adherence

No limitations
reported

Murru A, Pacchiarotti
I, Amann BL, Nivoli
AM, Vieta E, Colom F
2013 177

Novick D, Haro JM,
Suarez D, Perez V,
Dittmann RW,
Haddad PM 2010 178

Okpataku CI,
Kwanashie HO,
Ejiofor JI, Olisah VO
2015 179

To compare
correlations between
adherence and the
course of illness in
bipolar and
schizophrenia
patients
To assess the
predictors of
antipsychotic
adherence during
long-term
schizophrenia
treatment
To determine
medication
adherence behavior
in psychiatric outpatients with

303 outpatients on oral
antipsychotics

psychoactive
substance use
comorbidity

Olfson M, Mechanic
D, Hansell S, Boyer
CA, Walkup J,
Weiden PJ 2000 180

Owen RR, Fischer EP,
Booth BM, Cuffel BJ
1996 181
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Perkins DO, Gu H,
Weiden PJ, McEvoy
JP, Hamer RM,
Lieberman JA 2008 182

Pogge DL, Singer MB,
Harvey PD 2005 183

Pristach CA, Smith
CM 1990 184

Quach PL, Mors O,
Christensen TØ,
Krarup G, Jørgensen
P, Bertelsen M,
Jeppesen P, Petersen
L, Thorup A,
Nordentoft M 2009 185

To identify predictors
of medication
noncompliance in
patients with
schizophrenia
To examine the
effect of medication
noncompliance and
substance abuse on
symptoms of
schizophrenia
To evaluate
predictors of
medication
nonadherence in
patients recovering
from a first episode
of psychosis
To examine
antipsychotic
medication
adherence of
adolescents
To examine the
relationship between
patterns of alcohol
and drug use and
compliance to
medication among
schizophrenia
patients
To identify predictors
of poor medication
adherence among
patients with firstepisode
schizophreniaspectrum disorder

213 adult psychiatric
inpatients with a diagnosis of
schizophrenia or
schizoaffective disorder
prescribed antipsychotics

US

Prospective,
interview

A substance use disorder was a
predictor of medication
noncompliance (OR=4.6)

Recall bias, social
desirability

Short-term inpatients
schizophrenia

US

Prospective,
interview

Noncompliance was associated
with substance abuse

None reported

400 patients with
schizophrenia,
schizophreniform disorder,
or schizoaffective disorder

US

Prospective, RCT

Ongoing substance abuse was a
predictor of poor medication
adherence (p<.01)

Limited
generalizability

86 adolescent inpatients
prescribed olanzapine or
risperidone

US

Retrospective,
interview

A diagnosis of substance abuse
was significantly related to
nonadherence

Limited
generalizability

42 schizophrenic patients in
an acute care psychiatric unit

US

Cross-sectional,
interview

No significant difference in
compliance between alcohol
users and non-users

Could not
distinguish between
past and current
alcohol use

547 patients with firstepisode schizophreniaspectrum disorder

Denmark

Prospective,
interview

Substance abuse was a predictor
of low adherence (OR=2.03) at
1-year follow-up

None reported

Sajatovic M, Bauer
MS, Kilbourne AM,
Vertrees JE, Williford
W 2006 186

Sajatovic M, Blow FC,
Kales HC, Valenstein
M, Ganoczy D,
Ignacio RV 2007 187

Sajatovic M, Ignacio
RV, West JA, Cassidy
KA, Safavi R,
Kilbourne AM, Blow
FC 2009 188
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Sajatovic M,
Valenstein M, Blow
FC, Ganoczy D,
Ignacio RV 2006 189

Swanson AJ, Pantalon
MV, Cohen KR 1999
190

Swartz MS, Swanson
JW, Hiday VA,
Borum R, Wagner
HR, Burns BJ 1998 191

Teter CJ, Falone AE,
Bakaian AM, Tu C,
Ongür D, Weiss RD
2013 192

To evaluate factors
related to treatment
adherence among
veterans with bipolar
disorder
To evaluate patients
receiving
antipsychotic
medication using the
medication
possession ratio
(MPR)
To examine clinical
and subjective
variables in relation
to adherence in
bipolar patients
To examine
adherence with
psychotropic
medications among
patients with bipolar
disorder
To investigate the
effect of motivational
interviewing on
adherence among
psychiatric and
dually diagnosed
inpatients
To examine the joint
effect of substance
abuse and medication
noncompliance in
regard to the risk of
violent acts
To examine the
impact of substance
use disorder among
patients with bipolar
disorder in regard to
medication taking
behaviors

430 veterans diagnosed with
bipolar disorder

26,530 younger individuals
and 6,461 older individuals
prescribed antipsychotic
medication

140 patients with bipolar
disorder treated with mood
stabilizers in a mental health
clinic

32,993 veterans diagnosed
with bipolar disorder

121 psychiatric inpatients, 93
with a history of substance
abuse/dependence disorder

331 in patients with severe
mental illness

54 bipolar I disorder patients
at the Schizophrenia and
Bipolar Disorder Program at
McLean Hospital

US

Cross-sectional,
interview

A current substance use
disorder was a predictor of
nonadherence (p=.007) but any
past substance use disorder was
not

Low sample size,
adherence
measurement may
not be accurate

UK

Retrospective,
database analysis

Substance abuse was a predictor
of nonadherence in the older
population (OR=1.38) and the
younger population (OR=1.30)

Adherence
measurement may
not be accurate

Cross-sectional,
interview

Comorbid substance abuse is a
predictor of low adherence
(p<.01)

Cross-sectional
design limitations,
small sample size,
adherence
measurement may
not be accurate

US

Retrospective,
database analysis

Comorbid substance abuse
associated with treatment nonadherence (p<.0001)

Retrospective design
limitations, gender
homogeneity,
inability to validate
medical records

US

Prospective,
assessment of
motivational
interviewing
intervention

Brief motivational interventions
improve adherence among
dually diagnosed patients

Limited
generalizability, no
control group

US

Cross-sectional
and retrospective,
interview and
other data drawn
from a RCT

The combination of
noncompliance and
alcohol/substance abuse is
associated with serious violent
acts (p<.01)

Limited
generalizability,
could not establish
temporality

Cross-sectional,
interview

Patients with a past history of
SUD are more likely to adhere
to their medication regimen as
compared to patients with a
current SUD

Small sample size,
low generalizability

US

US

Wilk J, Marcus SC,
Westt J, Countis L,
Hall R, Regier DA,
Olfson M 2006 193

To compare clinical
characteristics of
nonadherence among
schizophrenia
patients with and
without past
comorbid substance
use disorders

190 patients with
schizophrenia and 105 with a
comorbidity of SUD and
schizophrenia

US

Cross-sectional,
questionnaire

Zivin K, Ganoczy D,
Pfeiffer PN, Miller
EM, Valenstein M
2009 194

To assess predictors
of antidepressant
adherence among
depressed veterans

20,931 and 23,182 veterans
registered in the VA who
have major depressive
disorder and received
antidepressants

US

Prospective,
database analysis

*Objectives directly reported from literature

Patients with a substance use
disorder were less likely to
discuss the risks of
nonadherence with their
provider (p=0.05), link
adherence to personal goals
(p=.006), or explore the
meaning of taking antipsychotic
medications with their provider
(p=0.01)
Patients with a substance abuse
disorder were more likely to
have poorer adherence at both 3
months (OR=2.18) and 6
months (OR=2.36)

Adherence
measurement may
not be accurate, no
clinical diagnosis,
limited
generalizability

Adherence
measurement may be
inaccurate
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d. Synthesis of results
Of the 51 studies included in the literature review, 36 studies (71%) concluded that
comorbid substance use was significantly associated with psychotropic medication
nonadherence.134,137,146-149,151-153,155,156,158-165,167,168,170,174-176,178,180-183,185-189,194 Eighteen of
these studies (35%) identified substance use as a predictor of
nonadherence.149,152,156,158,159,161-163,165,168,176,178,180,182,185-188 The rest simply found an
association between the two variables. Of these 35 studies, nine (18%) identified alcohol
abuse specifically as a factor associated with nonadherence134,147-149,156,162,167,170,178 and
three (6%) identified cannabis use as a factor.149,153,175 In regard to negative outcomes, six
studies (12%) found no significant relationship between substance use and psychotropic
medication adherence.154,166,169,177,179,184 Of these six studies, 1 (2%) specifically observed
alcohol use and found no relationship with nonadherence.184 One study (2%) included in
the review found mixed results of both negative and positive outcomes.150 This study
conducted by Colizzi et al. observed 205 patients with a first episode of psychosis in
order to identify the effect substance use and poor medication adherence has on health
outcomes. The researchers concluded that nonadherence was significantly associated with
nicotine dependence (OR=2.18), cannabis use (OR=2.86), and stimulant use (OR=2.63)
but was not associated with problem drinking. The remaining eight studies (16%)
identified additional conclusions that are further explained below.157,171-173,190-193

As stated, eight studies (16%) specifically observed the dual diagnosis population.155,171174,179,190,193

Two of these studies found a significant relationship between substance use

and nonadherence and one found no significant relationship. The first study, conducted
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by Herbeck et al., examined 342 patients with comorbid psychiatric and substance use
disorder and concluded that a current illicit drug problem was significantly associated
with nonadherence (OR=4.0).155 The second, conducted by Manwani et al., examined the
adherence patterns to mood stabilizers in 115 patients with bipolar disorder, of which 58
had a SUD and 57 did not. The researchers found that lifetime adherence was
significantly lower in the SUD group (65.9%) versus the non-SUD group (85.0%).174
Lastly, Okpataku et al. conducted a study in a Nigerian Tertiary Hospital observing
medication adherence behaviors in psychiatric outpatients with psychoactive substance
use comorbidities. The researchers found no statistically significant relationship between
substance use and medication adherence.179

Out of the eight studies observing the dual diagnosis population, five studies aimed to
identify the factors associated with psychotropic mediation nonadherence in patients with
dual diagnosis.134,171-173,193 The factors found to be associated with a higher level of
adherence included living in supported housing, having fewer stressful life events, and
lower mental illness symptom severity. Factors associated with lower adherence levels
were lower social support for drug and alcohol abstinence, less recovery-promoting
behaviors, lower satisfaction with medication, more severe medication side effects, lower
self-efficacy for drug avoidance, lower social support for recovery, the diagnosis of a
comorbid personality disorder versus other mental illnesses, lower functioning ability,
and the current use of illicit substances. The studies specific to the dual-diagnosis
population also concluded that these patients were less likely to discuss the risks of
nonadherence with their healthcare provider (p=.05), less likely to link adherence to their
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personal healthcare goals (p=.006), and less likely to explore the purpose of their
psychotropic medications with their healthcare provider (p=.01) when compared to
psychiatric patients without a comorbid substance use disorder.

The last study to observe the dual diagnosis population was conducted by Swanson et al.
The objective of the study was to investigate the effect motivational interviewing has on
adherence among the psychiatric and dual diagnosis population. The 121 enrolled
patients were split into two groups; one group received a standard treatment using
pharmacological and psychosocial methods while the second group received a standard
treatment along with an hour-long motivational interview given by a staff therapist. The
results showed that a significantly greater proportion of the motivational interview group
adhered to their treatment regimen after discharge. The researchers concluded that brief
motivational interventions show potential as effective tools for improving adherence in
the dual diagnosis population.190

The three remaining studies did not observe the dual-diagnosis population but did
identify additional conclusions. Swartz et al. set out to examine the effect of substance
abuse combined with medication nonadherence in regard to the risk of violent acts. 331
patients with severe mental illnesses were recruited from a previous randomized control
trial on involuntary outpatient commitment. Through face-to-face and telephone
interviews, the patients were asked questions related to violent acts such as whether they
have been arrested for physical or sexual assault, have gotten into a physical altercation
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that involved violent actions, or done anything that would cause a person to be afraid of
being harmed. Serious violent acts were defined as a violent act or a threat involving a
weapon or that resulted in an injury of another person. Adherence was measured through
self-report or the report of a family member. The researchers concluded that the
combination of nonadherence and alcohol or substance abuse is significantly associated
with serious violent acts (OR=2.29).191

In a study conducted by Teter et al., 54 inpatients who were hospitalized for bipolar
disorder were interviewed in order to examine the impact of substance use on medication
adherence. Psychiatric symptom rating scaled were administered in order to assess the
patient’s mental illness severity. Medication taking behaviors were observed daily by the
researchers and a standardized medication adherence ratio (SMAR) was calculated.
Patients were split into three categories; no substance use history, past substance use
history, and current substance use. The results showed that the SMAR of patients in the
current substance use group was significantly lower than patients in either the no
substance use history group or the past substance use history group.192

Lastly, Hunt et al. examined the medical records of 99 schizophrenia patients in order to
assess the effect of medication adherence and substance abuse on schizophrenia
outcomes. A patient was considered to be adherent to their medications if the records
suggested that he or she regularly took their medications at least 75% of the time. The
results showed that patients who were both non-adherent and abusing substances had the

58

highest readmission rate per patient (1.45 admissions) and accounted for more than half
of the hospital admissions in the cohort (58%). The researchers concluded that the
combination of both medication nonadherence and current substance abuse were
predictors of hospitalization.157

The studies included in the literature review had several self-reported limitations. The
most common self-reported limitation was that the measurement technique used to assess
adherence levels might be inaccurate (29 studies, 57%), with four studies specifically
citing recall bias and three studies citing desirability bias as a limitation. Another
commonly stated limitation was that the results from a study could not be generalizable to
the general population, which was reported as a limitation in 15 of the studies (29%).
Other limitations cited included the inability to establish temporality, the Hawthorne
effect due to patient knowledge of observation, possible selection bias, potential coding
errors, small sample size, and the inability to verify mental illness diagnoses.

IV.

Discussion
a. Summary of evidence

According to the evidence gathered by the systematic literature review, the consensus of
previous literature is that alcohol or illicit substance use is significantly associated with
psychotropic medication nonadherence. Although some of the included studies failed to
identify a significant correlation between the two factors, these studies accounted for a
small proportion of the all studies included in the review. As anticipated, no studies found
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substance abuse to be a predictor of increased medication adherence. A majority of the
studies observed patient populations with one specific mental illness while a limited
number more broadly assessed mental illness as a whole. Limited studies observed
factors in the dual diagnosis population specifically, even though that was the target
population for the review. No studies in the review observed relapse rates or the impact
of medication adherence upon substance abuse relapse, which is a vital health outcome of
substance use disorder treatment.

b. Limitations
From a review level, there were limitations that require addressing. As in most reviews,
the quality of studies varied. The studies included patient populations with various
different characteristics, therefore making it more difficult to compare outcomes study to
study. Lastly, there was a variation of how substance use was defined from study to
study. While some studies required patients to have a clinical diagnosis of substance use
disorder, others only required a self-report of substance use.

At the researcher level, multiple limitations could affect the review’s results. First, only
one investigator was in charge of identifying, collecting, and assessing the data from
previous literature, which could result in researcher bias. Another limitation was that nonEnglish studies were not included; therefore, studies written in foreign languages
containing relevant data may have been left out of the review.
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c. Conclusion
Overall, the literature shows that alcohol and illicit substance use is significantly
associated with medication nonadherence in the mentally ill population. The literature
review indicates a lack of research into the effect psychotropic medication nonadherence
has on the health outcomes of substance use disorder, especially substance use relapse.
The logical next step for future research would be to observe adherence factors
specifically in the dual diagnosis population and assess the affect adherence has on
patient relapse rates. Further data could help interventions tailor treatment to patients
more effectively, help overcome barriers to treatment, and improve overall health
outcomes.
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CHAPTER 3 – METHODS
I.

Study Methodology Overview

The study utilized a mixed methodology analysis consisting of a cross-sectional patient
interview, a retrospective facility record supplementation and validation, and a
prospective follow-up interview. Patients were evaluated within their first week of
treatment to assess history of substance abuse, mental illness symptom severity, and
adherence patterns prior to admission. Follow-up interviews were conducted at 1 and 2
months to reassess mental illness symptoms and adherence. Facility records were
accessed to cross-reference patient reported data.

II.

Data Source
a.

Location

Participants were recruited from the Salvation Army Harbor Light Center located on the
North Side in Pittsburgh, Pennsylvania. The Harbor Light Center is a medicallymonitored residential rehabilitation program that provides 90 days of treatment to men 18
years and older who desire recovery from alcohol and/or other substance abuse problems.
The services provided to the residents include individual and group counseling,
coordination of healthcare and behavioral health needs, education of daily living activity
skills, and referral to community supportive services.195 New admissions to the facility
(on average, 5 patients per week) receive an intake appointment where an extensive
clinical interview is conducted on relevant medical, psychiatric, and social
characteristics. Additionally, a medication interview with the patient is also conducted to
ascertain relevant pharmacy history.
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b.

Participants

Newly admitted patients (within the past week) to the Harbor Light Center were recruited
to participate in the study. Due to the intake policies of the rehabilitation center, patients
had to be male and at least 18 years of age. Patients eligible for the study further must
have had a self-reported diagnosis of a substance use disorder and at least one of the
following mental health diagnoses: (1) major depressive disorder, (2) generalized anxiety
disorder, (3) bipolar disorder, or (4) schizophrenia. For the purposes of this study,
patients were excluded from participation if they have been diagnosed with a substanceinduced psychiatric disorder, or if the facility record or patient report is unable to exclude
this possibility. If a Harbor Light Center counselor stated that a new intake was
experiencing severe withdrawal symptoms or they were having trouble adjusting to the
new environment, the researcher postponed the interview until the counselor confirmed
they were stable enough to participate in the study. The intake personnel were the first to
make the decision of whether or not a newly admitted patient met the exclusion and
inclusion criteria, and to make them aware of the ongoing study. This decision was then
confirmed by the researcher before initiating the primary interview.

III.

Data Extraction
a.

Recruitment procedure

Upon admission to the facility and completion of normal intake procedures, potential
patients identified to meet inclusion criteria by facility staff were offered the opportunity
to participate in the study. If the patient had any questions about the process of the study,
they would be answered initially by the intake personnel before enrollment. The intake
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facility was given the following study description in order to properly explain the study
procedures to the patient before they agreed to participate;
“Duquesne University is currently having a study at Salvation Army and
is looking for volunteers. We are studying the association between
substance abuse and taking your medications for depression, bipolar
disorder, anxiety, or schizophrenia. You will be asked questions about
your condition once today and again in 1 and 2 months for a follow-up.
The first interview will take about 30 mins and the follow-up will take
about 5 mins. Participation in this study will not affect your treatment in
the Salvation Army program. You will receive $10 for completing the first
interview and $10 for each follow-up ($30 total).”
The researcher then contacted the Harbor Light Center staff once per week in order assess
the number of patient that were interested in potential recruitment for the study. The
patient recruitment process began in October 2016.

b.

Informed consent procedure

After the patient confirmed they were interested in the study, the researcher conducted a
face-to-face meeting at the facility in order to explain the study and provide the
opportunity for informed consent. At this point the participants were given the Consent to
Participate in a Research Study form (APPENDIX 11) to review and sign. This form,
along with verbal guidance from the researcher, explained all the information needed in
order for the participant to provide informed consent. The form lists the investigators
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involved in the study and their contact information, as well as the contact information for
the university IRB chair. The participant was informed that any of the investigators may
be contacted in order to explain the study further or answer any questions about the study
procedures. The study purpose and participant procedures were then explained in order to
provide further clarification of the study. The risks and benefits of the study were listed to
explain to the participant that there are minimal risks associated with the participation but
are no greater than those encountered in everyday life. The compensation section
explains that the patient will receive $10 for completing the first in-person interview and
$10 for each follow-up for a total of $30. The study procedure for maintaining patient
confidentiality is also explained in the form, stating that their participation in the study
and any personal information that is provided will be kept confidential at all times and to
every extent possible. Health Insurance Portability and Accountability Act (HIPAA)
authorization is explained and states that the patients are aware that they are giving the
researchers permission to use their personal health information in their medication
records. All health information procedures in this study are HIPAA compliant, which is
explained further in the Subject Rights and Ethics section of this chapter. Lastly, the form
stated that participation in the study would be completely voluntary and that the
participant has the right to withdraw from the study at any time. As a patient at the
Harbor Light Center, the participants are under no obligation to participate in the study
and choosing not to participate or discontinuing participating will in no way affect the
services provided by the center. Once the researcher established with the participant that
they clearly understood all aspects of the study, the participants were then required to
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provide their signature on the Consent to Participate in a Research Study form and orally
confirm that they understood what they consented to.

c.

Primary interview

After informed consent was obtained, the researcher asked the patient if they wanted to
begin the study procedures at that same time. If the patient confirmed they wanted to
begin, the researcher then proceeded with the primary interview portion of the study. If
the patient requested a delay, a subsequent date and time was arranged. The interview
served two purposes: (1) measuring agreeance and supplementing data obtained from the
facility record review, and (2) providing additional evaluation through standardized and
validated assessment tools to assess medication adherence and psychological symptoms.
First, the interviewer utilized the Prospective Patient Interview Form (APPENDIX 2)
and recorded the patient’s responses. This researcher-created instrument was used to
collect information on patient-reported factors relating to mental illness, substance use
and relapse, medication history and behaviors, and comorbidities. Next, the Morisky
Medication Adherence Scale (MMAS-8) (APPENDIX 4) and the Drug Attitude
Inventory (DAI-10) (APPENDIX 5) were given to the patients to fill out themselves.
These instruments were used to collect information on the patient’s medication adherence
tendencies and their attitudes towards their medications. Lastly, depending on the selfreported mental illness diagnosis, the patients were given a questionnaire in order to
measure the severity of their mental illness. The Patient Health Questionnaire (PHQ-9)
(APPENDIX 6) was given to patients with major depressive disorder, the Mood Disorder
Questionnaire (MDQ) (APPENDIX 7) was given to patients with bipolar disorder, the
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Generalized Anxiety Disorder Assessment (GAD-7) (APPENDIX 8) was given to
patients with generalized anxiety disorder, and the Brief Psychiatric Rating Scale (BPRS)
(APPENDIX 9) was given to patients with schizophrenia. When filling out each form,
the patients were asked to consider their behavior during the month before entering
treatment in order to establish a set time period as a reference point. If a patient could not
fill out the questionnaires on their own, the researcher administered the questions
verbally and recorded the patient’s responses. After the interview was completed, the
researcher checked all forms for completeness, thanked the participant and processed the
reimbursement for their time and participation. The primary interviews took place from
November 1st, 2016 to June 20th, 2017.

d.

Follow-up interview

Two follow-up interviews were conducted at approximately one and two months postprimary interview. The follow-up time period was chosen due to the program length,
rehabilitation goals, and a literature review on relapse rates. Previous studies have found
that the largest drop in abstinence occurs within the first month (100% to 70%) and then a
leveling out occurs at three months.196 Before beginning the follow-up interview, the
researcher reiterated that the same confidentiality procedures from the primary interview
still applied, and asked if the participant had any questions before continuing. During this
interview, the interviewer utilized the Longitudinal Follow-up Interview Form
(APPENDIX 3). Data collected during the follow-up interview included assessment of
three key areas: (1) relapse to substance use, (2) status of mental illness symptoms, and
(3) status of medication adherence. Any patients who identified symptoms or presented
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remarks worrisome for relapse or mental health was offered the opportunity to speak with
care coordinators at the facility for intervention. If a patient left the program before
completing both of the follow-up interviews, they were coded as a drop-out and
information regarding why the patient left was collected from their facility counselors.
The primary interviews took place from November 29th, 2016 to June 20th, 2017.

e.

Facility record review

After the participant signed the Consent to Participate in a Research Study form and gave
informed consent, a facility record review was conducted by the co-investigator in order
to collect additional data on the patients’ risk factors for relapse into substance abuse.
The facility record data is initially collected by the Harbor Light center staff through an
intake interview along with other information obtained from the patient’s medical
records. The data collected through the facility record review included demographics,
history of substance use and relapse, history of mental illness and treatment, and medical
comorbidities. The co-investigator extracted data from the facility record using the
Facility Record Data Collection Form (APPENDIX 1).

IV.

Description of Variables
a.

Prospective patient interview form

The prospective patient interview form is a researcher-designed, 13-item instrument
consisting of four domains: (1) substance use and relapse, (2) mental illness diagnosis
and severity, (3) medication history and adherence behavior, and (4) medical
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comorbidities. The form begins by assessing when the patient checked into Salvation
Army Harbor Light Center, which was included to determine if the patient was eligible
for the study and to collect data on how long the patient has been in treatment prior to the
interview. The substance use and relapse section of the instrument assessed what the
patient’s primary drug of abuse was, how long the patient has been using said drug, and
what other illicit drugs the patient had used in their lifetime. The patient was then asked
to self-report how many times they have relapsed in their substance use and what factors
they believe have contributed to their relapse(s). Finally, the patient was asked how many
times they have been in treatment for substance use prior to their current admission to
Harbor Light.

The mental illness diagnosis and severity section begins by asking if the patient has ever
been diagnosed with a mental illness by a healthcare professional and if so, what the
diagnosis was. The patient’s mental illness severity was assessed by asking the patient to
think back to their mental illness symptoms prior to entering treatment while they were
still using alcohol or illicit drugs. This was utilized to provide a baseline prior to
treatment. The patient then self-reported their mental illness severity on a scale of 1 to 10,
with 1 referring to no symptoms and 10 referring to very severe symptoms. A list of
symptoms commonly related to depression, bipolar disorder, generalized anxiety, and
schizophrenia was included in order to help the patient assess the symptoms that were
particularly relevant.
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The medication history and adherence behavior section begins by asking the patient if
they have received any medication for their mental illness from a healthcare professional
and if so, what medications they currently were taking and what medications have they
previously taken. The patient is then asked to self-report their psychotropic medication
adherence both a month before coming to treatment while still using alcohol and illicit
substance and in their general lifetime. This adherence measure was scored on a scale of
1 to 10, with 1 referring to taking no doses and 10 referring to taking all doses as
prescribed. If the patient was unsure of what the term adherence means, the researcher
helped explain it to them in more detailed language. The patient was then asked what
factors they believe have contributed to them not properly taking their medications.

Lastly, the patients’ comorbidities were assessed by asking if they have ever been
diagnosed with any other chronic medical condition by a healthcare professional, such as
hepatitis C, diabetes, or high blood pressure and if so, what the diagnosis was. The
patient was also asked if they are currently taking any prescribed medications for these
comorbidities.

b.

Morisky Medication Adherence Scale (MMAS-8)

The Morisky Medication Adherence Scale (MMAS-8), a multidimensional self-reported
8-item measure, was utilized to assess the patients’ psychotropic medication adherence.
The MMAS-8 seeks to measure adherence by identifying the underlying factors that lead
to nonadherence such as forgetfulness, side effects, decreasing symptom severity, and
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complexity of the patient’s medical regimen.197-199 Each item measures a specific
adherence behavior and cannot be used individually as a determinant of adherence. The
first seven items of the MMAS-8 are dichotomous responses requiring a yes or no
response and the last item is a five-point Likert-scale. The items utilize reverse wording
resulting in both positive and negative questioning about adherence behaviors in order to
avoid desirability bias or patients giving only positive yes responses.200 The MMAS-8
scoring system is copyright protected and available for licensing from the originator. A
patient’s final score can be categorized low adherence, medium adherence, or high
adherence. As for psychometric properties, a 93% sensitivity and 53% specificity was
reported while validating the tool in a cohort of low income patients treated for
hypertension in an out-patient setting. The same study also reported a Cronbach’s alpha
value of 0.83, which is above the acceptance threshold of acceptability.200 The MMAS-8
was chosen as the adherence measurement for the study due to its popularity, common
usage in various clinical settings, widespread use in different diseases, populations, and
countries, high level of concordance with pharmacy fill data and electronic adherence
monitoring devices, and low response burden due to its conciseness. 201 The current study
utilized the general MMAS-8, although other condition and medication-specific forms of
the measure are available.

c.

Drug Attitude Inventory (DAI-10)

The Drug Attitude Inventory (DAI-10) (APPENDIX 5) was utilized to measure patient
attitudes and beliefs in regard to their prescribed psychotropic medications that may
contribute to their adherence levels. The DAI is a 10-item, true/false, self-reported
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measure that analyzes a patient’s subjective feelings towards medication. For example,
the DAI assesses if a patient believes that it is unnatural to take medication, if the good
things about medication outweigh the bad, or if they stop taking medication once they
feel better. In regard to scoring the DAI, questions that reflect a positive attitude towards
medication are scored as +1 if the patient answers true and -1 if the patient answers false,
whereas questions that reflect a negative attitude are scored as -1 if answered true and +1
if answered false. The total scoring of the DAI ranges from -10 to +10 with a total score
greater than 0 representing a positive attitude towards medications, a total score less than
zero representing a negative attitude towards medications and a total score of 0
representing a neutral attitude towards medication.202 Previous research has shown that
the reliability and validity of the DAI is similar to or greater than other common
medication adherence screening instruments when used within the mentally ill
population.203 The DAI was used in the study due to its ease of administration and low
response burden.

d.

Condition specific measures
i.

Patient Health Questionnaire (PHQ-9)

The Patient Health Questionnaire (PHQ-9) (APPENDIX 6) is a self-reported, 9-item
instrument designed to screen, diagnose, monitor, and measure the severity of major
depressive disorder (MDD). The PHQ-9, which was generated from the full 3-page PHQ
questionnaire, incorporates both DSM-IV diagnostic criteria along with other common
symptoms of depression. As stated, the PHQ-9 can be used as a diagnosis tool as well as
a severity measure. For a patient to be diagnosed with MDD, he or she must answer
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“More than half the days” or “Nearly every day” to question 1 and 2, must have 5 or
more of the symptoms present on more than half the days, and must have not checked
“not difficult at all” for question 10. When being used as a severity measure, the PHQ-9
score ranges from 0 to 27. A score of 5 represents mild, 10 represents moderate, 15
represents moderately severe, and 20 represents severe depression.204 The PHQ-9 has
been shown to have strong psychometric properties, with an internal reliability of 89%
and a test-retest reliability of 84%. The PHQ-9 has also been validated for criterion
validity and construct validity within the mental illness population.205 The PHQ-9 was
chosen to be used in the study due to its low response burden, simple scoring and
common usage in clinical settings.

ii.

Generalized Anxiety Disorder Assessment (GAD-7)

The Generalized Anxiety Disorder Assessment (GAD-7) (APPENDIX 8) is a 7-item
self-reported screening instrument for patients with generalized anxiety disorder. The
scale consists of 7 items related to the DSM-IV symptom criteria for GAD. The patients
reported how often they have experienced these symptoms over the past two weeks with
the options of selecting “Not at all”, “Several days”, “Over half the days”, and “Nearly
every day”. In order to score the GAD-7, each answer is given a weighted score (not at
all = 1, several days = 2, over half the days = 3, nearly every day = 4) and the scores are
added together to get a total score. Similar to the PHQ-9, the GAD-7 can be used as both
a diagnostic tool and a symptom severity measure. A score of 10 or more can be
interpreted as a probable diagnosis of GAD, which can be confirmed by further
psychiatric evaluation. As for severity, a score of 5 refers to mild anxiety, 10 refers to
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moderate anxiety, and 15 refers to severe anxiety.206 In a study conducted by Spitzer et
al., the psychometric properties of the GAD-7 were measured in a population of 2,740
adult patients in 15 primary care clinics. The researchers found a high internal
consistency of 92% and a test-retest reliability of 83%. In addition, the researchers also
concluded the GAD-7 had good criterion, construct, factorial, and procedural validity.206
The GAD-7 was chosen for this study due to its conciseness, ease of scoring, and strong
psychometric properties. While the GAD-7 was intended for screening, the study used it
as a measurement for severity. The GAD-7 has been established in previous literature as
a valid and efficient tool for assessing GAD severity in clinical practice and research.206

iii.

Mood Disorder Questionnaire (MDQ)

The Mood Disorder Questionnaire (MDQ) (APPENDIX 7) is a 15-item self-reported
screening instrument for patients with bipolar disorder. The instrument consists of five
questions, of which the first lists 13 items related to the DSM-IV symptom criteria for
bipolar disorder. The MDQ then assess if these symptoms occurred in the same period,
the impact of the symptoms on the patient’s life, whether the patient has a family history
of bipolar disorder, and if the patient has been previously diagnosed with bipolar
disorder. In order to receive a positive screening for bipolar disorder, the patient must
exhibit 7 of the 13 symptoms listed in question 1, must have experienced more than one
of these symptoms at the same time, and must report these symptoms have resulted in
either moderate or serious problems in their life.207 In a study conducted by Hirschfeld et
al., the psychometric properties of the MDQ were measured using a cohort of 198
patients at five outpatient psychiatric clinics. The results showed the MDQ has a high
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internal consistency of 90%. The researchers also found that the MDQ has a good
sensitivity (0.73; 95% CI: 0.65- 0.81) and a good specificity (0.90; 95% CI: 0.84-0.96).208
The MDQ was chosen for this study due to its timely and accurate evaluation of bipolar
disorder. Similarly, to the GAD-7, the MDQ was intended for screening but the study
used it as a measurement for severity which has been reported in previous literature.209

iv.

Brief Psychiatric Rating Scale (BPRS)

The Brief Psychiatric Rating Scale (BPRS) (APPENDIX 9) is a widely utilized, 18-item
instrument used to assess the positive, negative and affective symptoms in patients with
psychotic disorders, especially schizophrenia. Each item of the instrument gives a
description of a specific symptom related to psychotic disorders and the patient assigns a
number to each symptom that correlates with their self-reported severity, ranging from 1
(not present) to 7 (extremely severe). While there is no established total scoring criteria
for the BPRS, the scores of the 18 items can be added together and compared to other
patients or measured for change over time.210 While there is a lack of research into the
BPRS’s psychometric properties, one study conducted by Anderson et al. found that the
instrument has both adequate reliability (78%) and validity (66%) in the psychotic
population.211 The BPRS was chosen for this study due to its wide use in the psychiatric
field in order to assess patients with schizophrenia.
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e.

Longitudinal follow-up interview form

The Longitudinal Follow-up Interview Form (APPENDIX 3) is a researcher-designed, 6item instrument consisting of three domains: (1) substance use relapse, (2) mental illness
symptom severity, and (3) psychotropic medication adherence. The form begins by
asking the patient if he resumed the use of any alcohol or drugs since the last interview. If
the patients answered yes, the interviewer assessed when the relapse occurred and if the
patient has sought help. Then the patient was asked to report how their mental illness
symptoms have changed since the last interview, with the options of “no current
symptoms,” “symptoms decreased,” “symptoms increased,” and “symptoms remained the
same.” Similar to the Prospective Patient Interview Form, a list of symptoms commonly
related to depression, bipolar disorder, generalized anxiety, and schizophrenia is included
in order to help the patient assess their symptom severity level. Lastly, the patients were
asked to assess their adherence levels since the last interview on a scale of 1 to 10, with 1
referring to taking no doses and 10 referring to taking all doses as prescribed. If the
patient has not taken their medications as prescribed, they were asked what factors they
believed contributed to the nonadherence.

f.

Facility record data collection form

The Facility Record Data Collection Form (APPENDIX 1) is a 19-item form created by
the researchers to collect information on newly admitted patients from the facility intake
form. The form consists of four sections, which are patient demographics, history of
substance use and relapse, history of mental illness treatment and adherence, and medical
comorbidities. The data collected on patient demographic and social characteristics
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include age, race/ethnicity, employment status, income level, education background,
housing situation, and family support. The data collected on the patient’s substance use
and relapse history include the patient’s primary substance of use and other substances
used, age of first use, length of use, longest time clean, and number of admissions at
Harbor Light Center and other rehabilitation programs. Other rehabilitation program
stays were defined as any time a patient received inpatient or outpatient treatment for
their SUD outside of the Harbor Light Center. The data collected on patient mental
illness history include both patient-reported and medically-assigned mental illness
diagnosis, age of diagnosis, severity, pharmacological or non-pharmacological treatment
both current and previous, and medication adherence levels. The intake faculty
determines the patient’s mental illness severity level by assessing their signs of withdraw,
the presence of post-acute withdraw syndrome, visible SUD symptoms, psychological
and emotional drug cravings, mood stability, and presence of auditory or visual
hallucinations. Patient adherence levels are determined through the intake faculty
assessing the patient’s external and internal motivation. Lastly, the patient’s other
medical comorbidity diagnoses are assessed and reported.

V.

Data and Statistical Analysis
a.

Research objective 1

The first objective of the study was to identify personal, social and clinical histories for
patients with substance use disorder and either major depressive disorder, bipolar
disorder, schizophrenia or generalized anxiety disorder. Data for this objective was
collected from both the primary interview and the facility records. This objective was
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accomplished through a descriptive analysis of the following variables: age, race
(Caucasian and African American), employment status (unemployed, employed,
disabled), socioeconomic status (monthly income level), educational background (less
than high school, high school, more than high school), housing situation (homeless, living
with family, other), number of incarcerations, primary substance of use, number of
previous relapses, number of previous treatment stays, number of previous times at
Harbor Light, age of first substance use, mental illness diagnosis, mental illness severity
level, number of other medical comorbidities, and number of psychotropic medications
prescribed. The variables were broken down into the categories listed above in order to
make a proper analysis and compare the information. The data for this analysis was
primarily gathered through the facility data record collection with some supplementation
from data collected through the primary interviews. Data gathered from the facility data
record collection included age, race, employment status, socioeconomic status,
educational background, housing situation, number of incarcerations, number of previous
times at Harbor Light, and age of first substance use. Data collected through primary
interviews included primary substance of use, number of pervious relapses, number of
previous treatment stays, mental illness diagnosis, number of other medical
comorbidities, and number of psychotropic medications prescribed. Results were reported
using frequencies, means with standard deviations, and medians with ranges.

b.

Research objective 2

The second objective of the study was to identify discrepancies between patient selfreported data versus facility record data in regard to mental illness traits, substance abuse
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history, and psychotropic medication. This objective was accomplished through two
analyses of the following variables: primary substance of use, mental illness diagnosis,
number of mental illness comorbidities, number of psychotropic medications prescribed,
number of other comorbid diagnoses, and number of previous treatment stays. These
variables were chosen for this analysis due to them being collected at both the primary
patient interview and the facility data record collection. The above variables also play a
vital role in study’s other statistical analysis, therefore the accuracy of the patient selfreported should be confirmed. Cohen’s kappa coefficient was utilized to determine
agreement between self-reported and facility record data. This statistical analysis was
chosen over a simple percent agreement calculation due it being a more robust measure
that takes into account agreement occurring by chance.212

c.

Research objective 3

The third objective was to investigate the specific role of medication adherence and
barriers to use for psychotropic medications upon substance abuse relapse. Data for this
objective was collected from both the primary interview and the facility records. This
objective was completed through five separate analyses. First, patient demographic
characteristics were stratified by self-reported adherence rates, MMAS-8 total score, and
number of self-reported relapses. The variables observed in this analysis included age
(18-29, 30-39, 40-49, 50+), race/ethnicity, employment status, socioeconomic status,
education background, housing situation prior to entry, and number of incarcerations (0,
1, 2, 3+). The mean and standard deviation of adherence scores and relapses
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corresponding with each variable were reported then mean scores were assessed for
significant differences.

The patients’ substance abuse characteristics were then stratified by self-reported
adherence rates, MMAS-8 total score, and number of relapses. Substance abuse
characteristics included the variables of primary substance of use (heroin, alcohol, crack
cocaine, other), number of distinct drugs used (≤3, 4-9, 10+), and length of use (less than
10 years, 10 to 29 years, 30+ years). If there was a discrepancy between patient reported
data and facility records, patient reported data was used in the analysis.

The patients’ health related characteristics were then compared according to self-reported
adherence rates, MMAS-8 total score, and number of relapses. The mental illness
characteristics included in this analysis were mental illness diagnosis (MDD, GAD,
bipolar disorder, schizophrenia, more than 1 mental illness), self-reported mental illness
severity level (1-6, 7-9, 10), number of psychotropic medications prescribed (1-2, 3-4,
5+), presence of more than one mental illness (yes, no), PHQ-9 score (not present, mild,
moderate, moderately severe, severe), MDQ score (negative, positive), and GAD-7 (not
present, mild, moderate, severe). The BPRS scores were excluded from this analysis due
to only two patients having schizophrenia and both patients received similar scores for
severity level. Similar to the substance abuse characteristics, if there was a discrepancy
between patient reported data and facility records, patient reported data was used in the
analysis.
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The patients’ attitudes towards medications were then analyzed by stratifying the DAI
results by self-reported adherence rate, MMAS-8 total score, and number of relapses. The
total scores of the DAI were first compared according to adherence and relapses then
each question was broken down individually.

Patients’ adherence scores were correlated with the self-reported number of relapses in
order to assess the overall relationship between psychotropic medication adherence and
substance use relapse. Pearson’s correlation coefficient was utilized for this statistical
analysis. The four adherence measurements included were the MMAS-8 total score,
MMAS-8 intentional score, MMAS-8 unintentional score, and self-report adherence rate.

A multivariable logistic regression model was then created in order to assess the direct
impact psychotropic medication adherence has on relapse frequency. Patient
characteristics that were hypothesized to be a predictor of relapse were included in the
model. Said characteristics were MMAS-8 total score, self-reported mental illness
symptom severity level, mental illness type, length of substance use and DAI total score.
All variables except for mental illness type were classified as continuous variables.
Mental illness type was classified as a nominal variable composed of the following
groups: MDD, GAD, Bipolar, Schizophrenia, 2+.
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In regard to statistical analyses, t-test and ANOVAs were utilized for continuous
variables and chi square tests for categorical variables. When t-tests were used, Levene’s
test for equality of variance was utilized to assess variance within the data. For ANOVAs,
a test of homogeneity of variance was run to assess variance within the data. If there was
no significant variance, Tukey’s post hoc was then used to determine between which
variables the significant difference had occurred. If significant variance was present then
the Dunnett T3 statistic was used. As stated, Pearson’s correlation coefficient was utilized
for the correlation analysis. An a priori p-value of <0.05 was considered statistically
significant for all statistical assessments and effect sizes will be reported when
applicable, using Cohen’s d and odds ratio with a 95% confidence interval.

d.

Research objective 4

The fourth and final research objective was to assess follow-up changes in mental illness
severity and medication adherence in dual diagnosis patients enrolled in a substance
abuse rehabilitation program. Data for this objective was collected from both the primary
interview and the follow-up interviews. This was accomplished through three analyses.
First, the frequency and percentage of patients was reported according to which interview
they completed (primary interview only, 1st follow-up, 2nd follow-up). Second, patient
characteristics including age, MMAS-8 total score, MMAS-8 intentional score, MMAS-8
unintentional score, self-reported adherence rate, mental illness type, mental illness
symptom severity, substance of choice, DAI-10 total score, receiving income, and
housing situation were stratified according to follow-up interviews completed. Lastly,
changes in patients’ self-reported adherence from interview to interview were analyzed in
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order to assess for significant change in adherence over time while enrolled in the
rehabilitation program. The results in this analysis were reported in mean difference.

e.

Missing data

Missing data was not adjusted for in the statistical analysis of the study results. Due to the
methodological design of the study, the researchers concluded that missing data would
have no impact on the results of the study. The interviewer checked each form for
completeness during the primary interviews and follow-up interviews before the
interview concluded. If the patient missed any question, they were simply asked to
complete it before leaving, therefore there was no missing data from the primary data
collection step of the study. Patients who dropped out of the study were not considered
missing data. They were moved to the drop-out group of the study sample and analyzed
from that perspective. As for the facility data, only one patient had missing data for their
mental illness diagnosis. The patient self-reported a MDD diagnosis and the facility data
confirmed that the patient was prescribed the SSRI Prozac® and the antidepressant
Remeron®. Therefore, the researchers safely assumed that the patient was diagnosed with
MDD. Two patients had not reported their previous living status during their intake
interview but this played an insignificant role in the overall analysis. There were no other
cases of missing data prevalent in the data included in the statistical analysis.
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VI.

Data Capture

During the primary and follow-up patient interviews, information was collected using
paper data collection forms and was then transferred to a SPSS datafile. Data collected
through the facility record reviews were entered directly into an excel spreadsheet. The
Morisky Widget (MMAS Research LLC) was utilized in order to score and record the
results of the MMAS-8. Permission for use and a license agreement was obtained from
MMAS Research LLC. SPSS Statistics 22 (IBM; Armonk, NY) was utilized for all
statistical comparisons and modeling.

VII.

Subject Rights and Ethics

Due to the vulnerable nature of the study participants, enhanced care was given to
research ethics and subject rights. The study underwent and received a full board
approval by the Duquesne University Institutional Review Board, and the thesis
committee included a faculty member with specialized expertise in psychology, addiction
and research ethics for supervision. Before beginning any data collection, the researcher
confirmed that the participants fully understood the confidentiality protocol, their right to
withdraw, and HIPAA authorization, using both verbal and written explanations. All
health information procedures in the study were HIPAA compliant and no protected
health information (PHI) was recorded in any data collection procedure. Patient names
never appeared on any research instrument and their responses were only reported
through statistical data summaries. Each patient was given a study ID number in order to
keep their identity anonymous. A study ID log that matched each ID number to their
corresponding patient’s name was kept in a Harbor Light Center facility member’s office

84

and was only removed in order to conduct the patient record review process. All other
patient data collected throughout the study were kept confidential at all times and were
protected to every extent possible.

After completing patient interviews, the data collected was uploaded onto a password
protected computer located in the graduate student office located on Duquesne
University’s campus. The researchers had the sole access to the protected data. All
materials with personal or health information will be maintained for three years.
Electronic data will be manually deleted from the computer’s hard drive and all physical
material will be shredded by the researchers at the completion of the study.
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CHAPTER 4 – RESULTS
I.

Objective 1

Identify personal, social, and clinical history for patients with substance use disorder and
either major depressive disorder, bipolar disorder, schizophrenia, or generalized anxiety
disorder
a. Demographics
The final study sample consisted of 38 patients. The study data collection period took
place from November 1st, 2016 to June 20th, 2017. A majority of the patients were white
(n=27, 71.1%) and the rest were African American. The mean age of the patients was
40.8±11.4 years old. A total of 32 (84.2%) patients were unemployed and 7 (18.4%)
patients were receiving any form of income before entering treatment, with an
approximate monthly income level of $145.08 which includes those receiving no income.
Patients’ education level was somewhat evenly distributed, with 15 patients (39.5%)
having less than a high school education, 15 (39.5%) having a high school degree, and 8
(21.1%) having more than a high school education. The median number of incarcerations
was 1 with a range of 0 to 4. A majority of the patients were homeless before entering
treatment (n=30, 78.9%). The frequencies and percentages of patient demographics are
outlined in Table 2.
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Table 2: Demographic Characteristics
Demographic Characteristics
n (%) unless specified otherwise

Study Sample
(n=38)

Age (mean, st dev)
Race/ethnicity:
Caucasian
African American
Employment status prior to treatment:
Unemployed
Disabled
Employed
Approximate monthly income level ($) prior to treatment (mean, st dev)
Receiving any income prior to treatment:
Yes
No
Educational background:
Less than high school
High school
More than high school
Housing situation prior to treatment:
Homeless
Living with family
Other
Missing
# of incarcerations
Mean, st dev
Median, range

40.8 (11.4)
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27 (71.1)
11 (28.9)
32 (84.2)
4 (10.5)
2 (5.3)
145.08 (318.65)
7 (18.4)
31 (81.6)
15 (39.5)
15 (39.5)
8 (21.1)
30 (78.9)
2 (5.2)
4 (10.5)
2 (5.3)
1.2 (1.2)
1.0 (0-4)

b. Substance use characteristics
In terms of substance use characteristics, heroin was the most common primary drug of
use among patients (n=19, 50%), followed by alcohol (n=12, 31.6%), and crack cocaine
(n=4, 10.5%). Other substances used by patients included marijuana, methamphetamines,
cocaine, benzodiazepines, hallucinogens, opiates, buprenorphine/naloxone,
amphetamines, Robitussin®, and research chemicals. The average number of substances
used was 5.4 and the average length of substance use was 20.3 years, with the average
age of first substance use being 13.1 years old. The average number of rehabilitation
treatment center stays before entering Harbor Light was 6.1 stays. Lastly, the average
number of previous relapses was 9.7 among the patient population. The frequencies and
percentages of patient substance use characteristics are outlined in Table 3.
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Table 3: Substance Use Characteristics
Substance Use Characteristics
n (%) unless specified otherwise
Primary substance of use:
Heroin
Alcohol
Crack cocaine
Alcohol/cocaine
Marijuana
Methamphetamines
# of distinct substances used
Mean, st dev
Median, range
# of previous relapses
Mean, st dev
Median, range
# of previous treatment stays
Mean, st dev
Median, range
Length of substance use (mean, st dev)
Age of first use (mean, st dev)

Study Sample (n=38)

19 (50.0)
12 (31.6)
4 (10.5)
1 (2.6)
1 (2.6)
1 (2.6)
5.4 (2.8)
4 (1-10)
9.7 (14.1)
6 (0-75)
6.1 (6.0)
4 (0-25)
20.3 (13.7)
13.1 (3.0)
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c. Health-related characteristics
In regard to health characteristics, half of the patients (n=19, 50%) had two or more
mental illness diagnoses. The most common mental illness was the combination between
MDD and GAD (n=9, 23.7%), followed by MDD alone (n=7, 18.4%), and bipolar
disorder (n=6, 15.8%). Four patients had a combination of MDD, GAD, and bipolar
disorder. This combination of mental illness was the only instance of patients having
three or more comorbidities. On a scale from 1 to 10, the average self-reported mental
illness severity level was 8.39±1.93. Patients were prescribed an average of 2.3
psychotropic medications and the number of other comorbid diagnoses was 2.3. The
frequencies/percentages of patient health-related characteristics are outlined in Table 4.
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Table 4: Health-related Characteristics
Health-related characteristics
n (%) unless specified otherwise
Co-morbid mental illness:
Major depressive disorder (MDD)
Generalized anxiety disorder (GAD)
Bipolar
Schizophrenia
Comorbidity (2+ conditions)
MDD and GAD
Bipolar and Schizophrenia
MDD, GAD, and Bipolar
GAD and Bipolar
MDD and Bipolar
Self-reported mental illness severity
Mean, st dev
Median, range
# of other comorbid diagnoses
Mean, st dev
Median, range
# of psychotropic medications prescribed
Mean, st dev
Median, range

Study Sample (n=38)

7 (18.4)
4 (10.5)
6 (15.8)
2 (5.4)
19 (50.0)
9 (23.7)
2 (5.4)
4 (10.5)
2 (5.3)
2 (5.3)
8.39 (1.93)
9.0 (1-10)
2.3 (1.8)
1 (0-3)
2.3 (1.40)
2 (0-6)
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II.

Objective 2

Measure agreeance between patient self-report versus facility record history for mental
illness, substance abuse, and psychotropic medication
a. Patient-report and facility record comparison
Results from the patient interviews were compared to the facility medical records in order
to identify discrepancies and to test the agreeance of the patient self-reported data.
Cohen’s kappa, which measures the extent of agreement among data collected by two
different collectors, showed a significant agreeance in the reporting of primary substance
of use (κ=0.753, p<.001), mental illness diagnosis (κ=0.434, p<.001), number of mental
illness comorbidities (κ=0.257, p=0.008), and number of psychotropic medications
prescribed (κ=0.094, p<.001). Cohen’s kappa showed an insignificant agreeance between
patient self-report and facility records for number of other comorbid diagnoses (κ=0.094,
p=0.176) and number of previous treatment stays (κ=0.107, p=0.05). Patients reported
less comorbid diagnoses (median 1.0 vs 2.0) and more previous treatment stays (median
4.0 vs 3.0) when compared to facility records. The results of the patient-report and
facility record comparison are outlined in Table 5.
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Table 5: Patient Report vs Facility Record Data
Variables
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Primary substance of use:
Alcohol
Alcohol and cocaine
Crack cocaine
Heroin
Heroin and opiates
Marijuana
Methamphetamine
Opiates
Mental illness diagnosis
GAD
GAD and Bipolar
GAD, Bipolar, and MDD
GAD and MDD
Bipolar
Bipolar and MDD
Bipolar, MDD and Schizophrenia
Bipolar and Schizophrenia
MDD
MDD and Schizophrenia
Schizophrenia
Missing
# of mental illness comorbidities (median, range)
# of psychotropic medications prescribed (median, range)
# of other comorbid diagnoses (median, range)
# of previous treatment stays (median, range)

Patient interview
N (%)

Medical record
N (%)

12 (31.6)
1 (2.6)
4 (10.5)
17 (44.7)
1 (2.6)
1 (2.6)
1 (2.6)
1 (2.6)

17 (44.7)
0 (0.0)
1 (2.6)
19 (50.0)
0 (0.0)
0 (0.0)
1 (2.6)
0 (0.0)

4 (10.5)
2 (5.3)
4 (10.5)
9 (23.7)
6 (15.8)
2 (5.3)
0 (0.0)
2 (5.3)
7 (18.4)
0 (0.0)
2 (5.3)
0 (0.0)
2.0 (1-5)
2.0 (0-6)
1.0 (0-3)
4.0 (0-25)

4 (10.5)
0 (0.00
7 (18.4)
10 (26.3)
6 (15.8)
4 (10.5)
1 (2.6)
1 (2.6)
2 (5.3)
1 (2.6)
1 (2.6)
1 (2.6)
2.0 (1-4)
3.0 (1-7)
2.0 (0-9)
3.0 (0-8)

Cohen’s κ

0.753

p-value

<.001*

0.434

<.001*

0.257
0.240
0.094
0.107

<.001*
<.001*
0.176
0.052

III.

Objective 3

Investigate the specific role of medication adherence and barriers to use for psychotropic
medications upon substance abuse relapse

a. Measurement scores breakdown
i. MMAS-8
The Morisky Medication Adherence Scale (MMAS-8) was utilized to measure patient’s
adherence. The patients’ average score was 3.5±2.0, considered low adherence. A total of
33 (86.6%) of patients had low adherence, 4 (10.5%) had medium adherence, and only 1
patient (2.6%) had high adherence. Patients received similar average scores for both
intentional and unintentional adherence. The results for each individual question of the
MMAS-8 is shown in Table 6.
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Table 6: MMAS-8 Breakdown
MMAS-8 Question
Total score (mean, st dev)
1. Do you sometimes forget to take your pills?
Yes
2. People sometimes miss taking their medications for reasons other than
forgetting. Thinking over the past two weeks, were there any days when you did
not take your medicine?
Yes
3. Have you ever cut back or stopped taking your medication without telling your
doctor, because you felt worse when you took it?
Yes
4. When you travel or leave home, do you sometimes forget to bring along your
medication?
Yes
5. Did you take your medicine yesterday?
Yes
6. When you feel like your symptoms are under control, do you sometimes stop
taking your medicine?
Yes
7. Taking medication every day is a real inconvenience for some people. Do you
ever feel hassled about sticking to your treatment plan?
Yes
8. How often do you have difficulty remembering to take all your medications?
Never
Almost Never
Sometimes
Frequently
Always

Response
N (%)
3.5 (2.0)
30 (78.9)

22 (57.9)

23 (60.5)

27 (71.1)
30 (78.9)

23 (60.5)

20 (52.6)
1 (2.6)
14 (36.8)
15 (39.5)
6 (15.8)
2 (5.3)
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ii. DAI-10
The Drug Attitude Inventory (DAI-10) was given to the patients in order measure patient
attitudes and beliefs in regard to their prescribed psychotropic medications that may
contribute to their adherence levels. The cutoff point for the DAI is 0; therefore, a
negative score reflects a negative attitude, a score of 0 reflects a neutral attitude, and a
positive score reflects a positive attitude. The mean total score was 5.4±3.0 which reflects
a positive attitude towards medications. Almost all of the patients received a score above
0 (n=34, 98.5%), while three patients (7.9%) scored 0 and only one patient (2.6%) scored
below zero. The results for each individual question of the DAI-10 along with the total
scoring is shown in Table 7.
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Table 7: DAI-10 Breakdown
Drug Attitude Inventory (DAI-10)
Total score (mean, st dev)
Total score rating
Negative attitude (<0)
Neutral (0)
Positive attitude (>0)
1. For me, the good things about medication outweigh the bad
True
False
2. I feel strange, “doped up”, on medication
True
False
3. I take medications of my own free choice
True
False
4. Medications make me feel more relaxed
True
False
5. Medication makes me feel tired and sluggish
True
False
6. I take medication only when I feel ill
True
False
7. I feel more normal on medication
True
False
8. It is unnatural for my mind and body to be controlled by medications
True
False
9. My thoughts are clearer on medication
True
False
10. Taking medication will prevent me from having a breakdown
True
False
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Response
N (%)
5.4 (3.0)
1 (2.6)
3 (7.9)
34 (98.5)
34 (89.5)
4 (10.5)
12 (31.6)
26 (68.4)
33 (86.8)
5 (13.2)
31 (81.6)
7 (18.4)
19 (50.0)
19 (50.0)
8 (21.1)
30 (78.8)
32 (84.2)
6 (15.8)
13 (34.2)
25 (65.8)
27 (71.1)
11 (28.9)
27 (71.1)
11 (28.9)

b. Results stratified by adherence and relapse
i. Patients characteristics
Patient characteristics including age (18-29, 30-39, 40-49, 50+), race/ethnicity
(Caucasian, African American), employment status (unemployed, employed, disabled),
receiving income (yes, no), educational background (less than high school, high school,
more than high school), housing situation (homeless, living with family, other),
incarcerations (0, 1, 2, 3+), and number of comorbid health conditions (0, 1-2, 3-4, 5+)
were stratified according to total MMAS-8 score, self-reported adherence on a scale from
1-10, and self-reported relapse rate. The results showed that the group of patients who
were receiving income prior to admission had significantly higher mean relapse rates
compared to the group of patients who were not receiving income (16.9 vs 8.1, p=0.02).
The results of this analysis are shown in Table 8.
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Table 8: Patients Characteristics Stratified by Adherence and Relapse

Demographic Characteristic
Age
18-29
30-39
40-49
50+
Race/ethnicity:
Caucasian
African American
Employment status:
Unemployed
Disabled
Employed
Receiving income
Yes
No
Educational background:
Less than high school
High school
More than high school
Housing situation
Homeless
Living with family
Other
Incarcerations
0
1
2
3+
Number of comorbid health
conditions
0
1-2
3-4
5+
*Significant difference at p<0.05

Adherence
(MMAS-8 score;
mean, st dev)

Adherence
(self-report;
mean, st dev)

Relapses
(self-report; mean,
st dev)

3.6 (2.5)
3.9 (1.5)
3.9 (2.4)
2.4 (1.2)

3.3 (4.6)
3.6 (3.3)
2.9 (3.2)
2.1 (3.3)

6.3 (3.1)
5.7 (7.3)
11.5 (13.7)
15.5 (24.2)

3.5 (1.9)
3.7 (2.1)

2.9 (3.4)
3.6 (3.4)

11.7 (16.3)
4.8 (3.2)

3.5 (1.9)
5.2 (1.9)
1.5 (0.0)

2.8 (3.2)
5.5 (5.2)
2.0 (00)

8.9 (13.5)
7.3 (2.5)
29.0 (29.7)

4.1 (2.6)
3.4 (1.8)

2.7 (3.0)
4.6 (4.8)

16.85 (25.7)*
8.1 (9.9)*

4.2 (1.9)
3.5 (1.8)
2.5 (2.1)

3.1 (3.8)
3.7 (3.6)
1.6 (1.1)

8.5 (12.0)
7.4 (5.6)
16.1 (25.3)

3.5 (2.0)
2.4 (0.2)
3.9 (2.7)

2.7 (3.1)
2.0 (1.4)
5.0 (4.7)

10.1 (15.7)
5.5 (0.7)
11.0 (6.2)

3.2 (2.1)
4.0 (2.1)
4.3 (1.6)
2.3 (1.6)

2.0 (2.5)
3.6 (4.1)
3.5 (3.0)
4.2 (4.5)

13.8 (22.4)
7.9 (6.7)
7.3 (8.4)
6.8 (3.6)

4.5 (1.7)
3.5 (2.2)
3.6 (1.7)
1.3 (1.1)

3.3 (3.4)
2.7 (3.8)
2.3 (2.9)
6.0 (4.2)

7.0 (6.3)
6.3 (5.1)
16.3 (22.1)
4.3 (2.1)
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ii. Substance use characteristics
Substance use characteristics including primary substance of use (heroin, alcohol, crack
cocaine, other), number of distinct drugs used (≤ 3, 4-9, 10+), and length of use (less than
10 years, 10 to 29 years, 30+ years) were stratified according to total MMAS-8 score,
self-reported adherence, and self-reported relapse rate. The results showed that there were
no significant differences among these groups. The results of this analysis are shown in
Table 9.
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Table 9: Substance Use Characteristics Stratified by Adherence and Relapse
Substance Use
Characteristic
Primary substance of use:
Heroin
Alcohol
Crack cocaine
Other
# of distinct drugs used
≤3
4-9
10+
Length of use
Less than 10 years
10 to 29 years
30+ years

Adherence
(MMAS-8 score;
mean, st dev)

Adherence
(self-report;
mean, st dev)

Relapses
(self-report;
mean, st dev)

3.8 (2.1)
3.3 (1.7)
4.4 (1.8)
1.7 (1.7)

3.2 (3.7)
2.3 (2.6)
4.3 (4.4)
3.3 (4.0)

6.4 (5.9)
16.6 (22.6)
9.8 (7.6)
3.0 (1.7)

3.9 (2.4)
3.4 (1.9)
3.3 (1.5)

4.2 (4.1)
2.6 (2.9)
2.5 (3.4)

15.5 (24.1)
7.8 (7.0)
5.7 (2.3)

4.0 (2.0)
3.4 (1.9)
3.4 (2.2)

2.4 (2.4)
3.6 (3.6)
2.7 (3.7)

4.3 (3.1)
7.2 (6.7)
17.0 (22.4)
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iii. Mental illness characteristics
Mental illness characteristics including mental illness diagnosis (MDD, GAD, bipolar
disorder, schizophrenia, more than one mental illness), self-reported mental illness
severity level (1-6, 7-9, 10), number of psychotropic medications prescribed (1-2, 3-4,
5+), presence of more than one mental illness (yes, no), PHQ-9 score (not present, mild,
moderate, moderately severe, severe), MDQ score (negative, positive), and GAD-7 (not
present, mild, moderate, severe) were stratified according to total MMAS-8 score, selfreported adherence, and self-reported relapse rate. The BPRS scores were excluded from
this analysis due to only two patients having schizophrenia and both patients received
similar scores for severity level. The results showed that there were no significant
differences among these groups. The results of this analysis are shown in Table 10.
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Table 10: Mental Illness Characteristics Stratified by Adherence and Relapse

Mental Illness Characteristic
Diagnosis
MDD
GAD
Bipolar Disorder
Schizophrenia
More than one mental illness
Self-reported severity
Low (1-6)
Medium (7-9)
High (10)
Number of psychotropic
medications prescribed
1-2
3-4
5+
Presence of more than one
mental illness
Yes
No
PHQ-9
Not present (0-4)
Mild (5-9)
Moderate (10-14)
Moderately severe (15-19)
Severe (20-27)
MDQ
Negative screen
Positive screen
GAD-7
Not present (0-4)
Mild (5-9)
Moderate (10-14)
Severe (15+)

Adherence
(MMAS-8 score;
mean, st dev)

Adherence
(self-report;
mean, st dev)

Relapses
(self-report;
mean, st dev)

3.6 (2.0)
3.4 (2.3)
4.0 (2.5)
6.3 (2.5)
3.1 (1.6)

2.5 (3.3)
2.3 (1.0)
4.7 (4.1)
5.5 (6.4)
2.6 (3.3)

5.9 (3.8)
11.0 (10.9)
9.0 (8.6)
8.5 (2.1)
11.2 (18.8)

2.2 (2.0)
3.7 (1.7)
3.8 (2.1)

2.6 (2.5)
3.1 (3.8)
3.2 (3.4)

4.0 (2.5)
8.0 (5.3)
13.3 (20.8)

2.9 (1.4)
3.9 (1.7)
3.6 (2.9)

2.6 (3.5)
3.1 (3.4)
3.4 (3.6)

7.3 (5.5)
10.4 (17.0)
10.8 (14.9)

3.6 (1.8)
3.5 (2.2)

3.4 (3.7)
2.4 (2.7)

8.7 (7.3)
10.2 (16.7)

3.5 ( )
4.0 (1.3)
3.2 (2.2)
3.0 (1.8)

0.0 ( )
5.0 (4.0)
0.8 (1.0)
2.6 (3.6)

9.0 ( )
5.0 (2.2)
5.2 (4.0)
16.0 (23.9)

3.8 (1.7)
3.2 (2.1)

3.3 (2.6)
3.1 (3.6)

18.3 (22.9)
6.3 (5.1)

3.5 ( )
4.5 ( )
2.9 (1.7)
3.4 (1.9)

0.0 ( )
1.0 ( )
0.7 (1.2)
3.6 (3.5)

9.0 ( )
1.0 ( )
7.0 (1.7)
14.0 (22.1)
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iv. DAI-10
Patients’ total score on the DAI-10 along with each individual item were stratified
according to total MMAS-8 score, self-reported adherence, and self-reported relapse rate.
While there were no significant differences in terms of total scores, there was
significance at the individual item level. Patients who answered “True” to the statement
“For me, the good things about medication outweigh the bad” had significantly higher
self-reported adherence rate compared to those who answered “False” (3.3 vs 1.0,
p=.001). Patients who answered “True” to the statement “I feel strange, or doped up, on
medication” had significantly lower MMAS-8 scores (2.5 vs 4.0, p=.024) and
significantly lower self-reported adherence scores (1.3 vs 3.9, p=.030). Patients who
answered “True” to the statement “I take medications on my own free choice” had
significantly higher self-reported adherence (3.3 vs 1.6, p=.033). Patients who answered
“True” to the statement “It is unnatural for my mind and body to be controlled by
medications” had significantly lower MMAS-8 scores (2.3 vs 4.2, p=.004). Lastly,
patients who answered “True” to the statement “Taking medication will prevent me from
having a breakdown” had significantly higher MMAS-8 scores (4.0 vs 2.5, p=.035).
There were no significance differences in relapse rates for any questions in the DAI-10.
The results of this analysis are shown in Table 11.
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Table 11: DAI-10 Stratified by Adherence and Relapse

Drug Attitude Inventory (DAI-10)
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Total score
Negative (<0)
Neutral (0)
Positive (<0)
1. For me, the good things about medication outweigh the bad
True
False
2. I feel strange, “doped up”, on medication
True
False
3. I take medications of my own free choice
True
False
4. Medications make me feel more relaxed
True
False
5. Medication makes me feel tired and sluggish
True
False
6. I take medication only when I feel ill
True
False
7. I feel more normal on medication
True
False

Adherence
(MMAS-8
score; mean,
st dev)

Adherence
(self-report;
mean, st dev)

Relapses
(self-report;
mean, st dev)

0.5 ( )
3.1 (1.9)
3.7 (1.9)

1.0 ( )
6.3 (4.7)
2.8 (3.2)

10 ( )
26.3 (42.1)
8.2 (9.4)

3.6 (2.0)
3.1 (1.8)

3.3 (3.5)*
1.0 (0.0)*

9.7 (14.7)
9.3 (8.3)

2.5 (1.5)*
4.0 (2.0)*

1.3 (1.1)*
3.9 (3.8)*

11.6 (20.2)
8.8 (10.6)

3.5 (2.0)
3.7 (1.4)

3.3 (3.6)*
1.6 (0.9)*

10.6 (14.9)
3.4 (2.6)

3.7 (1.9)
2.8 (2.3)

3.2 (3.4)
2.3 (3.8)

7.9 (9.5)
17.4 (26.2)

3.2 (1.9)
3.9 (2.0)

3.5 (3.7)
2.6 (3.0)

7.5 (6.50
11.9 (18.9)

2.8 (1.4)
3.7 (2.1)

3.1 (2.9)
3.0 (3.6)

5.6 (3.4)
10.8 (15.7)

3.8 (1.9)
2.2 (1.6)

2.9 (3.3)
3.7 (4.2)

8.2 (9.7)
17.8 (28.2)

8. It is unnatural for my mind and body to be controlled by medications
True
False
9. My thoughts are clearer on medication
True
False
10. Taking medication will prevent me from having a breakdown
True
False

2.3 (1.5)*
4.2 (1.9)*

2.6 (3.0)
3.3 (3.6)

15.4 (22.6)
6.7 (5.0)

3.7 (2.0)
3.0 (1.9)

3.0 (3.5)
3.3 (3.3)

8.3 (9.6)
13.1 (21.9)

4.0 (2.0)*
2.5 (1.5)*

3.1 (3.5)
3.0 (3.2)

10.7 (16.1)
7.1 (7.2)
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c. Adherence measurements and relapse correlation coefficients
Correlation coefficients were computed among the four different measurements of
adherence and patients’ self-reported relapse rate. The four adherence measurements
included were the MMAS-8 total score, MMAS-8 intentional score, MMAS-8
unintentional score, and self-report adherence rate. The results of the correlation analyses,
presented in Table 12, showed that self-reported relapse rate was negatively correlated
with the MMAS-8 intentional score (r= -.360, p=.026). MMAS-8 total score was
positively correlated with self-reported adherence rates (r=.618, p<.001), the MMAS-8
intentional score (r=.869, p<.001), and the MMAS-8 unintentional score (r=.863,
p<.001). MMAS-8 intentional score was positively correlated with MMAS-8
unintentional score (r=.552, p<.001) and self-reported adherence rate (r=.613, p<.001).
Lastly, the MMAS-8 score was positively correlated with self-reported adherence rate
(r=.481, p<.001).
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Table 12: Correlation Between Adherence and Relapse
Pearson Correlation
Coefficient (r)

Self-report
Relapse Rate

MMAS-8
Total Score
MMAS-8
Intentional Score
MMAS-8
Unintentional Score
Self-reported
Adherence Rate

-.296

MMAS-8
Total Score

MMAS-8
Intentional Score

-.360*

.869**

-.139

.863**

.552**

-1.23

.618**

.613**

MMAS-8
Unintentional Score

.481**
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Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am
J Manag Care 2009;15(1):59-66. (3) Morisky DE, DiMatteo MR. Improving the measurement of self-reported
medication nonadherence: Final response. J Clin Epidemi 2011; 64:258-263.

108

d. Linear regression model
A multiple regression analysis was conducted to evaluate how well certain study
measures predicted self-reported relapse rate. The predictors were MMAS-8 total score,
self-reported mental illness symptom severity level, mental illness type, length of
substance use and DAI total score. All variables except for mental illness type were
classified as continuous variables. Mental illness type was classified as a nominal
variable composed of the following groups: MDD, GAD, bipolar disorder, schizophrenia,
2+ mental illnesses. The assumptions for linear regression models were assessed before
running the model. The Shapiro-Wilk Test was utilized to assess normality and the VIF
collinearity statistic was utilized to assess collinearity. The linear combination of the
study measures included in the model was not significantly related to self-reported
relapse rate (F=2.25, adjusted R2 =.145, p=.073). Table 13 shows the relative strength of
each individual predictor. The regression model shows that MMAS-8 total score is a
significant predictor of relapse rate when adjusting for the other included study measures
(stand. beta = -.443, CI= -6.37-0.23, p=.048).
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Table 13: Linear Regression Model
Self-report Relapse Rate (n=38)
Stand. beta
Constant

95% CI

p-value

-25.84 to 17.14

MMAS-8 total score

-.443

-6.37 to -0.23

0.048*

Mental illness symptom
severity (self-reported)

.314

-0.41 to 5.00

0.093

Mental illness type

-.141

-2.90 to 1.26

0.429

Length of substance use

.287

-0.30 to 0.62

0.074

DAI total score

.173

-0.98 to 2.37

0.402

*Significant difference at p<.05; Use of the ™©MMAS is protected by US and International trademark and
copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, MMAS
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Krousel-Wood M, Ward H. Predictive validity of a medication adherence measure for hypertension control. Journal of
Clinical Hypertension 2008; 10(5):348-354. (2) Krousel-Wood MA, Islam T, Webber LS, Re RS, Morisky DE,
Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care
2009;15(1):59-66. (3) Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication
nonadherence: Final response. J Clin Epidemi 2011; 64:258-263.
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IV.

Objective 4

Assess follow-up changes in mental illness severity and medication adherence in dual
diagnosis patients enrolled in a substance abuse rehabilitation program
a. Follow-up rates
As stated in previously, follow-up interviews were conducted with patients at one-month
and two months post-primary interview. A total of 12 patients (31.6%) fully completed
the study with two follow-ups, 15 patients (39.5%) participated in the first follow-up then
dropped out of the study, and 11 patients (28.9%) only participated in the primary
interview before dropping out. Reasons for patient drop-out included being caught using
drugs on the Harbor Light Center premises, not complying with center rules, not
believing that their addiction was severe enough to warrant treatment, overdosing on the
premise and being admitting to the hospital, being found in possession of illicit
substance, leaving the program to be with a significant other, leaving the program with
intention to continue substance use, completing the program early, testing positive for
illicit substances, using illicit substance while on leave, and simply leaving the program
without giving a reason.
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b. Patient and clinical characteristics by follow-up
Patient characteristics were stratified according to follow-up interviews completed. The
characteristics included in this analysis were age, MMAS-8 total score, MMAS-8
intentional score, MMAS-8 unintentional score, self-reported adherence rate, mental
illness type, mental illness symptom severity, substance of choice, DAI-10 total score,
receiving income, and housing situation. The results of this analysis are shown in Table
14. The DAI-10 total score was significantly lower in patients who only completed the
primary interview vs. patients who completed the study entirely (4.0 vs 7.0, p=.044). All
other comparisons were statistically insignificant.
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Table 14: Patient and Clinical Characteristics by Follow-up
Characteristics
Mean, st dev unless specified
Age
MMAS-8 total score
Adherence (self-report)
Mental illness type, n (%)
MDD
GAD
Bipolar
Schizophrenia
2+
Symptom severity
Drug of choice, n (%)
Heroin
Alcohol
Crack cocaine
Alcohol and crack
Marijuana
Methamphetamine
DAI total score
Relapse rate (self-report)
Receiving income, n (%)
Yes
No
Housing situation, n (%)
Homeless
Living with family
Other

Primary
(n=11)
41.2 (11.5)
3.2 (1.5)
3.8 (3.5)

1st Follow-up
(n=15)
40.5 (11.1)
3.2 (1.8)
2.6 (3.3)

2nd Follow-up
(n=12)
40.8 (12.7)
4.3 (2.0)
2.9 (3.6)

1 (2.6)
1 (2.6)
2 (5.3)
1 (2.6)
6 (15.8)
8.2 (1.5)

2 (5.3)
1 (2.6)
3 (7.9)
0 (0.0)
9 (23.7)
8.3 (2.5)

4 (10.5)
2 (5.3)
1 (2.6)
1 (2.6)
4 (10.5)
8.8 (1.4)

4 (10.5)
4 (10.5)
2 (5.3)
0 (0.0)
1 (2.6)
0 (0.0)
4.0 (2.8)*
8.5 (8.0)

9 (23.7)
4 (10.5)
1 (2.6)
0 (0.0)
0 (0.0)
2 (5.3)
5.1 (2.3)
10.6 (18.5)

6 (15.8)
4 (10.5)
1 (2.6)
1 (2.6)
0 (0.0)
0 (0.0)
7.0 (3.4)*
9.7 (13.0)

0 (0.0)
11 (28.9)

3 (7.9)
12 (31.6)

4 (10.5)
8 (21.1)

9 (25.0)
0 (0.0)
1 (2.8)

13 (36.1)
0 (0.0)
1 (2.8)

8 (22.2)
2 (5.6)
2 (5.6)

p-value
0.990
0.300
0.667

0.670

0.748

0.634

0.044*
0.933
0.117

0.272

*Significant difference at p<.05; Use of the ™©MMAS is protected by US and International trademark and
copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, MMAS
Research) LLC; 14725 NE 20th St.; Bellevue, WA 98007. Pertinent citations include: (1) Morisky DE, Ang A,
Krousel-Wood M, Ward H. Predictive validity of a medication adherence measure for hypertension control. Journal of
Clinical Hypertension 2008; 10(5):348-354. (2) Krousel-Wood MA, Islam T, Webber LS, Re RS, Morisky DE,
Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care
2009;15(1):59-66. (3) Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication
nonadherence: Final response. J Clin Epidemi 2011; 64:258-263.
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c. Changes in adherence
At each interview, patients reported their adherence on a scale from 1 to 10. These selfreported adherence rates were analyzed in order to assess for significant change in
adherence over time while enrolled in the rehabilitation program. The results showed a
significant change in adherence during the first follow-up interview compared to the
primary interview (mean difference=5.7, p<.001) and a significant change in adherence
during the second follow-up interview compared to the primary interview (mean
difference=6.5, p<.001). There was no significant change in adherence between the first
follow-up interview and the second follow-up interview. The results of this analysis are
shown in Table 15.
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Table 15: Changes in Adherence
Adherence (self-report) Mean difference (st dev) p-value
Primary interview vs.
1st follow-up

5.7 (3.7)

<.001*

Primary interview vs.
2nd follow-up

6.5 (3.7)

<.001*

1st follow-up vs.
2nd follow-up

0.17 (0.9)

0.551

*Significant difference at p<.05
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CHAPTER 5 – CONCLUSION
I.

Discussion

The overall goal of the study’s first objective was to gain better insight into the dual
diagnosis patient population. The demographic data collected through the study
demonstrated that the study population is an extremely vulnerable population who need
both mental health and substance use treatment. The study population is characterized as
predominately indigent, of lower educational status, homeless, white, middle-aged men.
The majority of these men were engaging in the use of drugs such as heroin or crack
cocaine, and have been using drugs since they were young teenagers. The results of this
long-term use are highlighted by the high amount of comorbid health conditions in the
patients. The high rate of previous substance use treatments and relapse rates may lead
one to extrapolate that these patients are somewhat aware that they are engaging in an
unhealthy and dangerous lifestyle but they lack the ability to stop even if they are actively
trying to. While the previous statement is a plausible conclusion, it is important to be
cognizant of the fact that SUD is a defined mental illness driven by addiction and
characterized by irrational behavior.

The population also suffers from severe mental illnesses, and in most cases more than
one diagnosis. During the primary interviews, patients were given both mental illness
severity measurement tools and asked to self-report their symptom severity on a scale
from 1 to 10. The results from the mental illness severity measurements and patient selfreport show that not only are the patients suffering from severe mental illnesses but they
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are also aware of the severity of their symptoms. Yet, patients in this population are not
taking the medications prescribed to them to aid in the treatment of their diagnoses. Both
the patient’s self-report and the MMAS-8 show that adherence to psychotropic
medications is severely low within this population. The overwhelmingly positive results
of the DAI-10 show that patients are fully aware of the benefits of psychotropic
medications yet still lack the ability to take them as prescribed. When asked why they
were not taking their medications properly, a majority of patients cited reasons related to
their drug habits such as ‘being too inebriated to remember’ and fearing dangerous drug
interactions. Many patients even displayed an awareness that they are self-medicating
their mental illness with illicit drugs. The concepts of cognitive impairment and selfmedicating may offer an explanation of why there is a gap between patients knowing
their condition yet not taking their medications. Cognitive impairment is a common
symptom of both SUD and mental illness that harms certain areas the patient’s mental
functioning including critical thinking, memory, attention, and motivation.213 Therefore,
patients in the study may lack the cognitive ability to maintain a prescription regimen
even when they are actively trying. In regard to self-medicating, previous literature has
proven that this is a common problem within the dual diagnosis population. In a large
nationally representative survey of 43,093 adults with mental illness, Bolton et al. found
that 25% of individuals with mental illness used drugs or alcohol to relieve their
symptoms.214 Therefore, it can be concluded that patient within our study may be actively
choosing to relieve their mental illness symptoms using illicit drugs even if they are
aware of the benefits of psychotropic medications. In other words, the patients may
simply prefer drugs of abuse over psychotropic medications.
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Outside of mental impairment and self-medicating, another way to explain the conflicting
beliefs of patients being aware of their mental illness and wanting to recover from their
substance abuse problem yet not taking their medications is to conclude that patients are
not aware of how properly treating their mental illness will benefit their goal of quitting
substance abuse. Patients may believe that their mental illness and SUD are two unrelated
diseases that are to be treated separately. Therefore, they may be currently attempting to
treat their SUD through rehabilitation while not properly treating their co-occurring
mental illness.

The results from the study’s first objective are on par with previous literature. First our
study concluded found that the study population suffered from a high level of mental
illness symptom severity. Previous studies have also concluded that patients with SUD
are likely to suffer from more severe mental illness symptoms compared to those who do
not have a SUD. For example, a study conducted by Ries et al. measured the mental
illness severity in 104 patients admitted to an acute voluntary psychiatric unit. The study
concluded that patients with a current SUD had significantly more severe symptoms
compared to those who did not.215 Secondly, our study found that the patients included in
the study displayed an extremely low level of adherence. As discussed in the literature
review, psychotropic medication nonadherence is common in patients with SUD. Our
literature review found that 36 of the 51 studies (71%) concluded that comorbid
substance use was significantly associated with psychotropic medication nonadherence.
134,137,146-149,151-153,155,156,158-165,167,168,170,174-176,178,180-183,185-189,194 134,137,146-149,151-153,155,156,158-

165,167,168,170,174-176,178,180-183,185-189,194

Of these 36 studies, 18 (35%) identified substance use
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as a predictor of nonadherence. Yet, these studies vary in adherence measurement
methods when compared to our study. In a previous study conducted by Dunn et al., the
MMAS-8 scale was used to measure medication adherence in 316 patients with cooccurring psychiatric disorders and SUD enrolled in an addiction treatment program. It
appears that this is the only other study that has utilized the MMAS-8 scale in the dual
diagnosis population. The researchers concluded that 80.4% of the patients enrolled in the
study scored as adherent on the MMAS-8.216 These results are contrary to both the results
found in our study and the results found in the majority of the studies within the literature
review. Lastly, our study’s first objective found that patients displayed an overall positive
attitude towards their psychotropic medications according the DAI-10 results. In a
previous study conducted by Cuevas et al., 270 psychiatric outpatients were given the
DAI-10 along with 292 citizens with no history of mental illness or psychotropic
medications. The psychiatric patients showed an overall more positive attitude compared
to the general population, with a mean DAI-10 score of 3.6 compared to -0.7.217 These
DAI-10 scores are similar to the overall DAI-10 mean of 5.4 that was measured in our
study population.

The goal of the study’s second objective was to measure agreeance between patient-self
reported data using facility records in order to determine if the dual diagnosis population
is a reliable source of data for research. While the majority of the data collected from the
facility records was patient self-reported, the patients’ mental illness diagnosis and
medications prescribed were supplemented by medical records. It is important to test this
relationship not only to confirm the agreeance of the data but also to test patients’ disease
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insight, which is the ability to understand the nature of their illness. Patients with low
disease insight are more difficult to treat and experience worse health outcomes.218
Before conducting the study, it was hypothesized that the data gathered from patients
would be somewhat inaccurate due to the mental state of the patients who are providing
the data. Multiple previous studies have measured disease insight in patients with heroinuse disorder,219 bipolar disorder,220 schizophrenia,221 depression222 and mental illness in
general.223 These studies have unanimously concluded that patients in their respective
population exhibit significantly low disease insight or awareness. Contrary to our
hypothesis and previous research, the patients in our study displayed a high awareness
and knowledge of their current health status by accurately reporting information about
their mental illness diagnoses and psychotropic medications. The high correlation
between patients’ report of adherence and all three MMAS-8 scores also highlights the
accuracy of the adherence information provided by patients. This finding may be due to
the Harbor Light intake protocol and the other processes the patients go through before
admission. The majority of patients come to Harbor Light from detoxification or other
health care settings such as hospitals emergency departments. In these settings and
through Harbor Light intake procedures, patients may have been reminded of their
disease states. Since the primary interview took place within a week of admission, the
patients were more likely to remember their mental illness compared to others in the dual
diagnosis population. It is important to note that agreeance was higher for primary
substance of use compared to the other variables. The researchers hypothesize that this
outcome occurred due to substance use history being the only patient controlled variable
included in the analysis.
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The goal of the study’s third objective, which was the primary objective of the study, was
to investigate the specific role of medication adherence and barriers to use for
psychotropic medications upon SUD relapse. The results of the DAI-10 stratification
showed that low adherence is a result of patients having negative attitudes towards their
psychotropic mediations or not believing that these medications play a vital role in their
mental illness treatment yet it was found that these attitudes and beliefs do not play a role
in patients relapsing back to substance use. The researchers hypothesize that the
insignificant relapse outcome was caused by large standard deviations due to only one
patient expressing negative attitudes and 34 expressing positive attitudes. The conclusion
that negative attitudes towards psychotropic medication leads to low adherence is
supported by previous literature. In a study conducted by Brown et al, attitudes and
beliefs about antidepressant medications were measured in patients in a primary care
setting. Patients’ attitudes were measured using the Beliefs about Medicines
Questionnaire (BMQ), the measurement that the DAI-10 is based on. The researchers
concluded that positive beliefs about medications were significantly associated with selfreported adherence.224 Another study conducted by Brain et al. observed the effect of
drug attitude on medication adherence in 112 outpatients with schizophrenia and
schizophrenia-like psychosis. The DAI-10 was utilized to measure drug attitudes and a
medication event monitoring system was utilized to measure adherence. A univariate
regression model showed that a negative DAI-10 score was a predictor of nonadherence.225
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The study’s third objective also found that there was a significant correlation between
patients’ nonadherence to psychotropic medications and SUD relapse. This relationship
was then analyzed further using a regression model, which concluded that the linear
combination of the included variables was not significant. The researchers hypothesized
that this outcome was due to the influence of the underpowered study sample size on the
model’s F statistic, even though all 38 patients were included in the model and no
missing data was prevalent. Yet, the model concluded that adherence is a significant
predictor of substance abuse relapse when other study variables were incorporated into an
adjusted analysis. Therefore, the results of the study can lead one to conclude that dual
diagnosis patients’ nonadherence to psychotropic medications is related to substance
abuse relapse. Our study is currently the first study in the literature to observe this
specific relationship within the dual diagnosis population and to make this conclusion.

While there may be multiple explanations as to why a relationship was found, the act of
self-medicating may explain the gap between psychotropic medication nonadherence and
SUD relapse. Patient were not adherent their psychotropic medications due to multiple
factors including negative attitudes towards their medications. As discussed in the
background section, nonadherence leads to increased mental illness symptom severity. As
their symptoms increase, patients may be choosing to treat their mental illness with illicit
drugs instead of prescribed medication therefore leading them back to SUD relapse. A
study focused on patients self-medicating would need to be conducted in the future in
order to confirm this hypothesis.
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The goal of the study’s fourth and final objective was to assess differences between
patients who stayed in the study versus those who did not and to observe changes in
behavior while in rehabilitation. This was done by following patients over three months
through follow-up interviews. Less than one third of the total participants continued the
study to its completion. This high drop-out rate was initially expected due to the nature of
the study population. All patients who dropped out of the study also dropped out of the
rehabilitation program, therefore no patient specifically chose to discontinue study
participation while still pursing treatment. Patient drop-outs were simply a secondary
result of patients not continuing drug addiction treatment and was not due to the study
itself. The drop-out rate within our study is similar to substance abuse treatment program
dropout rates found within previous literature. The typical treatment drop-out rate within
the first month of treatment is 30% and the rate rises to 50% at 3 months.226 Our study
had a drop-out rate of 28.9% within the first month and a drop-out rate of 68.4% at three
months. The study found that patients who completed the entire study displayed more
positive attitudes and beliefs towards the psychotropic medications they are prescribed.
Since all patients who dropped out of the study also discontinued their substance abuse
treatment, this relationship offers valuable insight into the importance of patients fully
understanding why they should be taking their medications and the vital role it plays in
rehabilitation. Lastly, the study found that patients’ adherence increased over time while
in the rehabilitation center. Harbor Light Center’s staff does not force patients to take
their mediations nor do they monitor medication taking behavior at a clinical level.
Therefore, one can conclude that the drug abuse rehabilitation intervention played a
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significant and vital role in increasing psychotropic adherence which, as the study has
shown, decreases their likelihood of substance abuse relapse.

II.

Study Implications

The results of the study provide valuable insight into the relationship between
psychotropic medication adherence and substance abuse relapse in patients with dual
diagnosis. It is evident from the study findings that dual diagnosis patients’ adherence
and attitudes towards their psychotropic medication play a significant role in substance
use relapse. The results of the study can be applied to real-world treatment of dual
diagnosis in the following ways.

First, the study results provide a better understanding into the dual diagnosis population
and can be used by drug abuse rehabilitation programs in order to target patients more
effectively and increase treatment outcomes. Interventions can now identify patients that
are at a higher risk of substance use relapse therefore giving them the ability to provide
more centralized and individually tailored treatment to those who need it the most. Since
the main outcome of most rehabilitation interventions is preventing substance use relapse,
an increased understanding of what causes that outcome is extremely valuable.
Interventions should incorporate education about the importance of psychotropic
medication adherence and mental illness treatment into their programs therefore helping
patients attain their cessation goals. While Harbor Light does encourage their patients to
take their psychotropic medications, adherence should become an integral part of their
treatment program. Periodic assessments of adherence should take place while patients
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are in treatment in order to guarantee that patients are staying adherent. Harbor Light
should also provide adherence counseling and adherence motivational interviewing to
their patients. As discussed in the literature review, standard SUD treatment combined
with motivational interviewing has been shown to significantly increase adherence
among dual diagnosis patients.190 The most noteworthy challenges of working within this
population was the patients’ lack of accuracy and reliability when reporting health-related
variable. Therefore, these counseling sessions should also focus on improving health
literacy in order to increase disease awareness and improve outcomes. Since our study
found that negative attitudes towards medications are related to nonadherence, these
counseling sessions should also educate patients on the short-term and long-term effects
of medication, how the medication works, and the role adherence plays in SUD
treatment.

Second, the results from the study can be utilized by healthcare professionals. The study
highlights the importance of physicians integrating the treatment of mental illness and
SUD in dual diagnosis patients due to the negative effect each disease has on the other.
SAMHSA has recently published a report, titled Integrated Treatment for Co-Occurring
Disorders: The Evidence, which highlights the importance of integrated dual diagnosis
treatment along with previous evidence that concluded combined treatment results in
more positive outcomes.227 The third objective of our study found that nonadherence is
related to SUD relapse. Therefore, physicians should provide adherence counseling to
patients with a history of SUD before they are prescribed psychotropic medications and
continuously through their treatment. These counseling sessions should consist of
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adherence strategies, expected side effects, potentially dangerous drug-drug interactions,
and the benefits on staying adherent. Phone counseling can be utilized to ease the burden
on patients who are unable to or not willing to return to the physician’s office. Since selfreported adherence may not be accurate in this population, physicians could use
electronic pill bottles to measure adherence behaviors more accurately between
appointments. Since these patients are uniquely difficult to treat using typical mechanism
such as primary care, social and case workers may also be more effective in
implementing these changes.

The results of our fourth objective highlight the importance of following-up with patients
after they leave treatment in order to guarantee the continuation of adherence. While
follow-ups may be more difficult to conduct in this population, many techniques can be
utilized. Short message service (SMS) based interventions have been shown to both
improve adherence in patients with mental illness 228 and improve drug abstinence in dual
diagnosis patients.229 Significant others or family members without SUDs could also be
included to help prevent patients discontinuing the interventions. The use of mobile
interventions will result in a faster detection of nonadherence therefore giving
interventions the ability to provide help before the patient reverts back to illicit drug use.

III.

Limitations

The study contains some potential limitations that may have impacted the results, and
need to be addressed in order for the study outcomes to be properly interpreted. First, due
to some study characteristics, the results may not be generalizable. The study finished
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data collection with low sample size due to it being intentionally designed as a feasibility
study. Also, the study only contained males in the sample since Harbor Light Center is a
male only facility. Therefore, the results may not be generalizable to females with dual
diagnosis. The study only included patients with major depressive disorder, generalized
anxiety disorder, bipolar disorder, and schizophrenia. Although these are among the most
prevalent mental illnesses, the results may not be generalizable to patients with other
mental illnesses such as attention-deficit disorder or post-traumatic stress disorder.

Second, the information reported by patients may be subject to recall bias. Almost all of
the information collected from the patients is retrospective and the patients may have
been cognitively impaired during that time period. For example, one patient was required
to recall the number of relapses he experienced during a 40-year history of substance use.
The inclusion of facility records attempted to minimize this effect since the patients’
mental health information was supplemented by health records.

Third, the results may be subject to social desirability bias. Since all patients were
interviewed within their first week of treatment, patients may have embellished their
adherence levels or restrained from revealing all of their past substance use in order to
exhibit their ability to succeed in the program. Also, question #9 of the PHQ-9 asked the
patients if they have ever had “Thoughts that you would be better off dead or of hurting
yourself in some way.” One patient expressed a concern that there would be
consequences if he answered that question honestly. The impact of social desirability bias
should be minimal due to the study design. The researcher began each interview by
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reiterating to the patient that no information would be shared with the Harbor Light
Center staff and that the interview would have no effect on their treatment in the
program. If the patients were aware that the information they gave during interviews was
completely confidential, there would be no reason to embellish or lie about their
adherence levels or substance use characteristics.

Fourth, the patients’ low health literacy may have affected the accuracy of the selfreported data. Multiple patients showed signs of not fully understanding the concept of
adherence, even after it is explained to them. For example, patients often self-reported a
‘10’ on adherence but then admitted to occasionally missing doses. One patient selfreported a ‘10’ on adherence but admitted to breaking all of his pills in half for every
dose so the medication lasted longer. He also saw nothing wrong with doing this since it
was saving money. In reality, this would be classified as extremely low adherence or
even considered zero adherence. The researcher thoroughly explained the concept of
adherence to each patient and expressed willingness to explain any material to patients
during all interviews. The interviewer also attempted to assess if the patient understood
all of the questions included in the self-reported assessments. Therefore, the impact of
this limitation should not be significant. Similar future research should consider
measuring patient health literacy and adjusting for it within the statistical analysis.

IV.

Opportunities for Future Research

Based on the results of the study, one can conclude that psychotropic nonadherence plays
a significant role in regard to substance abuse relapse in the dual diagnosis population.
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While this is a significant and impactful finding, further research is needed in order to
gain a more in-depth understanding in regard to the connection between adherence and
SUD relapse. The researchers suggest that future studies take the following approaches.
First, a larger study with a greater sample size and wider geographic coverage observing
the same relationship would produce a better understanding of the relationship. Second,
while the study established nonadherence as a predictor of relapse, a more in-depth study
analyzing the causation of nonadherence within the dual diagnosis population would
better help interventions improve adherence therefore preventing relapse. The researchers
suggest a more in-depth qualitative study surrounding patients self-medicating in order to
discover why patients are choosing illicit drugs over psychotropic medications for
treating their psychiatric symptoms. These studies should also establish a more accurate
approach to measuring symptom severity across the sample. While our study used
established tools such as the PHQ-9 and the MDQ, these results could not be compared
across disease states. Third, while the study established that adherence improved while in
treatment, no information was gathered on patients after they completed the program or
dropped out. Patients’ adherence levels were established during the primary interview
and measured through the 90-day treatment period. While the study concluded that
adherence improved during this period, this conclusion cannot be assumed to hold true
after the patient leaves the program since they are going from a controlled environment to
an uncontrolled environment. A future study should follow patients for a longer amount
of time, even after rehabilitation completion, collecting substance abuse and relapse
information in order to assess if the changes in adherence made during treatment are
permanent. This may prove to be difficult since a majority of the patients were homeless
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before admission. We suggest researchers conduct phone interviews or invite patients to
return back to the facility after completing the program and establish a way to pay the
patients for their time. A future study should also conduct exit interviews with patients
who completed the program in order to assess variables that influenced successful
treatment. Lastly, a future study should assess the impact of a rehabilitation centers
educating patients on the importance of adherence in order to determine if interventions
that focus on increasing patient knowledge in regard to adherence would indeed lead to a
decrease in relapse.
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APPENDICES
APPENDIX 1: Facility Record Data Collection Form
1. Patient ID:

2. Year of birth:
3. Race/ethnicity (Caucasian, Black/African American, Hispanic, other):
4. Employment status prior to relapse:
5. Approximate income level prior to admission:
6. Educational background (less than high school, high school, more than high
school):
7. Housing situation prior to admission:
8. Description of family support:
9. Primary substance of abuse/choice:
a. Other substances utilized:
10. Age at substance use initiation:
11. Length of use reported:
12. Number of previous admissions to Harbor Light facility:
13. Number of other admissions to rehabilitation programs:
14. Mental illness diagnoses:
a. Patient-reported:
b. Medically-assigned:

15. Age at mental illness diagnosis:
16. Severity of mental illness prior to admission:
17. Mental illness treatments (pharmacological or non-pharmacological):
a. Previously utilized:
b. Currently prescribed:
18. Level of medication adherence:
19. Medical comorbidity diagnoses:
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APPENDIX 2: Prospective patient interview form
1. What is your primary drug of abuse? What other drugs have you utilized in addition to
your primary drug of abuse?
2. How long have you been using your primary drug of abuse?
3. How many times have you relapsed in your substance use prior to this facility?
4. How many times have you been in treatment for substance use prior to this facility?
5. What factors do you believe have contributed to your relapse this time?
6. Have you ever been diagnosed with a mental illness by a healthcare professional? If so,
what diagnoses?
7. Think back to your mental illness symptoms prior to entering treatment (excluding
withdrawal symptoms). On a scale of 1 to 10 (1 = no symptoms and 10 = very severe
symptoms), how would you rate the severity of your mental illness symptoms (insert
appropriate example below)?
a.
b.
c.
d.

Depression – e.g. low energy, lack of appetite, lack of motivation
Bipolar disorder – e.g. mood swings, periods of excessive energy or depression
Generalized anxiety – e.g. persistent worrying, inability to relax, distress
Schizophrenia – e.g. hallucinations, delusions

8. Have you received any medication for your mental illness from a healthcare professional?
a. If so, what medications are you currently taking?
b. If so, what medications have you previously taken?
9. Often times, people do not take their medication as prescribed. On a scale of 1 to 10 (1 =
taken no doses and 10 = taken all doses as prescribed), how would you rate adherence to
your medication for your mental illness?
10. What factors do you believe have contributed to you not taking your medication?
11. Have you ever been diagnosed with other long-term medical conditions by a healthcare
professional, such as hepatitis C, diabetes, high blood pressure? If so, what diagnoses?

147

APPENDIX 3: Longitudinal follow-up questions
1. Since leaving the Harbor Light facility, have you resumed use of any alcohol or other
drugs of abuse (for example, prescription opioids, cocaine, marijuana, or heroin)?
2. If relapsed, how long after leaving the Harbor Light facility did this occur?
3. If relapsed, have you sought treatment for your substance use?
4. Since leaving the Harbor Light facility, how have your symptoms of your mental illness
changed (insert appropriate example(s) of symptoms below) – (1) no current symptoms,
(2) symptoms deceased, (3) symptoms increased, (4) symptoms remained the same?
Please explain.
a.
b.
c.
d.

Depression – e.g. low energy, lack of appetite, lack of motivation
Bipolar disorder – e.g. mood swings, periods of excessive energy or depression
Generalized anxiety – e.g. persistent worrying, inability to relax, distress
Schizophrenia – e.g. hallucinations, delusions

5. Often times, people do not take their medication as prescribed. Since leaving the Harbor
Light facility, on a scale of 1 to 10 (1 = taken no doses and 10 = taken all doses as
prescribed), how would you rate adherence to your medication for your mental illness?
6. If you have not taken your medication as prescribed, what factors do you think have
contributed to you not taking your medication?

[Offer for contact with care coordinator at Harbor Light if patient expresses increased
symptoms or reports relapse to substance use]
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APPENDIX 4: The Morisky Medication Adherence Scale (MMAS-8)
Use of the ™©MMAS is protected by US and International trademark and copyright
laws. Permission for use is required. A license agreement is available from: Donald E.
Morisky, MMAS Research) LLC; 14725 NE 20th St. Bellevue WA 98007.
Pertinent citations include:
▪

▪

▪

Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive validity of a
medication adherence measure for hypertension control. Journal of Clinical
Hypertension 2008; 10(5):348-354.
Krousel-Wood MA, Islam T, Webber LS, Re RS, Morisky DE, Muntner P. New
medication adherence scale versus pharmacy fill rates in seniors with
hypertension. Am J Manag Care 2009;15(1):59-66.
Morisky DE, DiMatteo MR. Improving the measurement of self-reported
medication nonadherence: Final response. J Clin Epidemi 2011; 64:258-263.
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APPENDIX 5: The Drug Attitude Inventory (DAI-10)

Hogan TP., Award AG., Eastwood R. A self report scale predictive of drug compliance in
schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177–183.
Reproduced with permission
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APPENDIX 6: The Patient Health Questionnaire (PHQ-9)

Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a Brief Depression
Severity Measure. Journal of General Internal Medicine. 2001;16(9):606-613.
doi:10.1046/j.1525-1497.2001.016009606.x.
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APPENDIX 7: The Mood Disorder Questionnaire (MDQ)

Hirschfeld RMA. The Mood Disorder Questionnaire: A Simple, Patient-Rated Screening
Instrument for Bipolar Disorder. Primary Care Companion to The Journal of Clinical
Psychiatry. 2002;4(1):9-11.
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APPENDIX 8: The Generalized Anxiety Disorder Assessment (GAD-7)

Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. A brief measure for assessing
generalized anxiety disorder: the GAD-7. Archives of Internal Medicine.
2006;166(10):1092–1097. https://doi.org/10.1001/archinte.166.10.1092
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APPENDIX 9: The Brief Psychiatric Rating Scale (BPRS)

Overall JE. Gorham DR. The brief psychiatric rating scale. Psychological reports. 1962
10:799-812.
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APPENDIX 10: Patient screening tool
For Salvation Army Harbor Light facility staff:
If during an intake interview, a new patient meets ALL of the following criteria (check
off):
 Male sex
 At least 18 years of age
 Admitted to Salvation Army Harbor Light
 Dual diagnosis of substance abuse disorder and either:
o

Major depressive disorder

o

Bipolar disorder

o

Generalized anxiety disorder

o

Schizophrenia

If a patient has evidence of a substance-induced psychiatric disorder, they are NOT
ELIGIBLE.
If the patient meets these above criteria, please make the following offer:
“There is currently a research study being conducted here at the Salvation Army
Harbor Light facility that is looking to determine if adherence to medications for
mental health conditions has any connection to relapse in substance use. Would
you be interested in speaking with someone regarding participating in this
study?”
If the patient expresses interest after this offer, please contact one of the study
investigators.
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APPENDIX 11: Consent to Participate in a Research Study Form

DUQUESNE UNIVERSITY
600 FORBES AVENUE  PITTSBURGH, PA 15282

CONSENT TO PARTICIPATE IN A RESEARCH STUDY
TITLE: Non-adherence to psychotropics and risk for substance use disorder relapse among
patients with dual diagnosis
INVESTIGATORS:
Tyler Dunn

Masters student
Duquesne Univ Mylan School of Pharmacy

Minha Choi

Bachelors/Pharm.D. student
Duquesne Univ Mylan School of Pharmacy

Jordan R Covvey, PharmD, PhD, BCPS

Assistant Professor
Duquesne Univ Mylan School of Pharmacy

412.396.2636

Khalid M Kamal, MPharm, PhD

Associate Professor
Duquesne Univ Mylan School of Pharmacy

412.396.1926

Lauren Jonkman, PharmD, MPH, BCPS

Assistant Professor
Univ of Pittsburgh School of Pharmacy

412.648.8563

Vincent Giannetti, PhD

Professor
Duquesne Univ Mylan School of Pharmacy

412.396.6379

SOURCE OF SUPPORT:
This study is being performed as partial fulfillment of the requirements for the Masters degree in
Pharmacy Administration (Dunn) and a Bachelors degree in Pharmaceutical Sciences (Choi) at
the Duquesne University Mylan School of Pharmacy.
PURPOSE:
You are being asked to participate in a research study that is evaluating whether medication
adherence (taking your medication as directed) for depression, bipolar disorder, generalized
anxiety or schizophrenia and substance use disorder has a connection to substance abuse
relapse.
To participate in the study, you must be male, at least 18 years of age and part of the residential
program at the Salvation Army Harbor Light facility. You must also report a diagnosis of a
substance use disorder and either major depressive disorder, bipolar disorder, generalized
anxiety or schizophrenia. The study aims to determine if adherence to medications for these
conditions is connected with lower rates of relapse in substance use.

156

PARTICIPANT PROCEDURES:
To participate in this study, you will be asked (1) to provide permission to access to your Harbor
Light record to collect information about you and your health and medication history, (2) to
participate in an interview with one of our study investigators to answer questions about
medication, substance use and your mental health, and (3) permission to contact you at one (1)
and (2) months after the interview for follow-up questions regarding medication, substance use
and your mental health. The in-person interview is expected to take approximately 30-45 minutes
and the follow-up phone calls should take approximately 5-10 minutes each. Study investigators
will take notes on paper during your interview and phone calls. These are the only requests that
will be made of you.
RISKS AND BENEFITS:
For the interview and phone calls, you will be asked questions regarding your mental health
history. If you experience any stress or become tired while talking with the study investigator, you
will be allowed to stop and take a break. You do not have to answer questions that you do not
want to answer. The study investigators will also view and collect more data from your Harbor
Light record. However, at no point will you receive any physical or mental treatment within the
study. You are only providing information to the study investigators.
You are free to stop study participation at any time. There are minimal risks associated with this
participation but no greater than those encountered in everyday life. There are no direct benefits
to you, but the information from the study could help to provide better support and treatment to
others with substance abuse in the future.
COMPENSATION:
Your time and participation in the study will be reimbursed in cash based on your level of
participation. If you are enrolled in the study, you will receive $10.00 for completing your inperson interview, and $10.00 for follow-up phone calls at 1-month and 2-months (a total of $30.00
maximum per person). This payment will be provided as the study continues. Participation in the
project will require no monetary cost to you.
CONFIDENTIALITY:
Your participation in this study and any personal information that you provide will be kept
confidential at all times and to every extent possible.
Your name will never appear in any data entry and will only be used to conduct interviews and
follow-up. Instead, you will be given a study number (Patient 1, 2, 3…) which will keep your
identity anonymous in all recorded data. All written and electronic forms and study materials will
be kept secure. After completion of the study, the information collected will be uploaded and
stored on a secure computer until the data analysis is complete. Your response(s) will only
appear in statistical data summaries. Any study materials with personal identifying information will
be maintained for three years after the completion of the research and then destroyed.
If while during the study or follow-up you express concerns that require clinical help (such as
suicidality), study investigators will be required to inform facility personnel.
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HIPAA AUTHORIZATION:
You understand that by participating in this study, you are giving us permission to use your
personal health information in your medical record and information that can identify you. The
health information procedures in this study are HIPAA compliant. Any health protected
information obtained will be stored by the researcher for six years after the completion of the
study.
RIGHT TO WITHDRAW:
You are under no obligation to participate in this study and may stop participation at any time.
Initial enrollment or any subsequent discontinuation from the study will in no way affect services
provided or accessed within the Harbor Light Center. You are free to withdraw your consent to
participate at any time by communicating your wish to your study investigator or any Harbor Light
staff member.
SUMMARY OF RESULTS:
A summary of the results of this research will be supplied to you, at no cost, upon request.
VOLUNTARY CONSENT:
I have read the above statements and understand what is being requested of me. I also
understand that my participation is voluntary and that I am free to withdraw my consent at any
time, for any reason. On these terms, I certify that I am willing to participate in this research
project.
I understand that should I have any further questions about my participation in this study, I may
call Dr Covvey at 412.396.2636, Dr Kamal at 412.396.1926 or Dr Giannetti at 412.396.6379.
Should I have questions regarding protection of human subject issues, I may call Dr. David
Delmonico, Chair of the Duquesne University Institutional Review Board, at 412.396.1886.

________________________________________
Participant's Signature (Patient ID =
)

__________________
Date

________________________________________
Researcher's Signature

__________________
Date
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